{
  "ada_2025_enhanced_diabetes_knowledge_graph": {
    "metadata": {
      "version": "4.0.0",
      "created_at": "2025-01-15",
      "updated_at": "2025-01-15",
      "description": "基于ADA 2025标准和CGM共识的最新糖尿病知识图谱",
      "total_entities": 757,
      "total_relationships": 2010,
      "inference_rules": 89,
      "clinical_cases": 44,
      "api_endpoints": 35,
      "languages": ["zh-CN", "en-US"],
      "medical_guidelines": [
        "ADA Standards of Medical Care in Diabetes 2025",
        "ADA/EASD Consensus Report on Type 2 Diabetes Management 2024",
        "International Consensus on CGM 2024",
        "AACE/ACE Diabetes Guidelines 2024",
        "Endocrine Society Clinical Practice Guidelines 2024",
        "ADA Position Statement on Diabetes Technology 2024",
        "中华医学会糖尿病学分会指南2024",
        "American Dietetic Association Nutrition Guidelines 2025",
        "ACSM Exercise Testing and Prescription Guidelines 12th Edition",
        "ACSM/ADA Joint Position Statement on Exercise and Diabetes"
      ],
      "key_updates_2025": [
        "新的糖尿病分型系统",
        "CGM和GMI作为标准监测指标",
        "个体化HbA1c目标设定",
        "新型降糖药物循证证据",
        "数字化健康技术整合",
        "健康公平性考量",
        "医学营养治疗标准化",
        "运动处方个体化",
        "营养运动协同效应",
        "心理健康全面整合",
        "急性并发症规范处理",
        "妊娠糖尿病专业管理"
      ],
      "cgm_consensus_integration": {
        "consensus_organizations": [
          "ADA", "EASD", "AACE", "IDF", "ISPAD", "ATTD"
        ],
        "publication_year": "2024",
        "evidence_level": "A级推荐"
      }
    },
    "entities": {
      "physiological_entities": [
        {
          "id": "PHYS_006",
          "name": "葡萄糖管理指标",
          "name_en": "Glucose Management Indicator",
          "type": "biomarker",
          "category": "CGM衍生指标",
          "description": "基于连续血糖监测数据计算的估算HbA1c值，反映近期血糖管理状况",
          "patient_friendly_desc": "GMI是根据您的连续血糖监测数据计算出的估算糖化血红蛋白值",
          "clinical_significance": "ADA 2025推荐的标准血糖评估指标，与传统HbA1c互补",
          "properties": {
            "calculation_formula": "GMI(%) = 3.31 + 0.02392 × 平均血糖(mg/dL)",
            "si_unit_formula": "GMI(%) = 3.31 + 0.02392 × 平均血糖(mmol/L) × 18",
            "data_requirement": "至少70%的CGM数据完整性",
            "reporting_period": "标准14天，最长90天",
            "normal_range": {
              "target_range": "<7.0%（与HbA1c目标一致）",
              "excellent_control": "<6.5%",
              "good_control": "6.5-7.5%",
              "fair_control": "7.5-8.5%",
              "poor_control": ">8.5%"
            },
            "advantages": [
              "实时反映近期血糖控制",
              "不受血红蛋白变化影响",
              "便于频繁监测和调整",
              "患者即时反馈"
            ],
            "limitations": [
              "需要CGM设备",
              "短期波动较大",
              "与实验室HbA1c可能存在差异",
              "成本相对较高"
            ],
            "correlation_with_hba1c": {
              "correlation_coefficient": "r=0.84-0.92",
              "mean_difference": "通常差异<0.5%",
              "agreement_analysis": "Bland-Altman分析显示良好一致性"
            }
          },
          "clinical_applications": {
            "primary_uses": [
              "实时血糖管理评估",
              "治疗方案快速调整",
              "患者教育和激励",
              "临床试验终点指标"
            ],
            "recommended_populations": [
              "1型糖尿病患者",
              "胰岛素治疗的2型糖尿病",
              "妊娠糖尿病",
              "HbA1c不可靠的患者"
            ]
          },
          "ada_2025_recommendations": {
            "evidence_level": "A",
            "recommendation_strength": "强推荐",
            "clinical_guidance": "GMI应与传统HbA1c结合使用，提供更全面的血糖控制评估"
          }
        },
        {
          "id": "PHYS_007",
          "name": "目标范围内时间",
          "name_en": "Time in Range",
          "type": "cgm_metric",
          "category": "CGM核心指标",
          "description": "血糖在目标范围内的时间百分比，CGM的核心评估指标",
          "patient_friendly_desc": "TIR表示您的血糖在理想范围内的时间比例，就像血糖控制的成绩单",
          "clinical_significance": "ADA 2025强烈推荐的血糖控制质量核心指标，与并发症风险密切相关",
          "properties": {
            "standard_definition": {
              "target_range": "3.9-10.0 mmol/L (70-180 mg/dL)",
              "measurement_unit": "百分比(%)",
              "reporting_basis": "24小时连续监测数据"
            },
            "clinical_targets": {
              "adults_type1_type2": {
                "excellent": ">85%",
                "good": "70-85%",
                "acceptable": "50-70%",
                "poor": "<50%"
              },
              "pregnancy": {
                "target": ">90%",
                "tight_range": "3.5-7.8 mmol/L (63-140 mg/dL)"
              },
              "elderly_high_risk": {
                "modified_target": ">60%",
                "rationale": "平衡获益与低血糖风险"
              },
              "pediatric": {
                "target": ">70%",
                "age_considerations": "根据年龄和发育阶段调整"
              }
            },
            "complementary_metrics": {
              "time_above_range": {
                "tar_level1": "10.1-13.9 mmol/L (181-250 mg/dL)",
                "tar_level2": ">13.9 mmol/L (>250 mg/dL)",
                "target": "TAR <25% (Level 1), <5% (Level 2)"
              },
              "time_below_range": {
                "tbr_level1": "3.0-3.8 mmol/L (54-69 mg/dL)",
                "tbr_level2": "<3.0 mmol/L (<54 mg/dL)",
                "target": "TBR <4% (Level 1), <1% (Level 2)"
              }
            },
            "clinical_correlations": {
              "hba1c_relationship": "每10% TIR改善约对应0.5% HbA1c改善",
              "complication_risk": "TIR每增加10%，视网膜病变风险降低15%",
              "hypoglycemia_safety": "TIR提高同时TBR降低最为理想"
            }
          },
          "calculation_methods": {
            "basic_calculation": "目标范围内读数 / 总读数 × 100%",
            "data_requirements": {
              "minimum_wear_time": "70%的时间佩戴",
              "minimum_duration": "连续14天",
              "data_quality": "排除校准失败和传感器错误"
            },
            "standardized_reporting": "AGP报告标准格式"
          },
          "clinical_interpretation": {
            "improvement_strategies": [
              "识别高血糖模式和原因",
              "优化餐时胰岛素时机和剂量",
              "调整基础胰岛素或基础率",
              "生活方式干预指导"
            ],
            "pattern_analysis": [
              "黎明现象识别",
              "餐后血糖控制",
              "夜间低血糖风险",
              "运动相关血糖变化"
            ]
          }
        },
        {
          "id": "PHYS_008",
          "name": "血糖变异性",
          "name_en": "Glycemic Variability",
          "type": "cgm_metric",
          "category": "CGM高级指标",
          "description": "血糖波动的程度和模式，反映血糖稳定性的重要指标",
          "patient_friendly_desc": "血糖变异性衡量您的血糖波动程度，稳定的血糖对健康更有益",
          "clinical_significance": "高血糖变异性与并发症风险增加相关，是血糖管理的重要目标",
          "properties": {
            "measurement_parameters": {
              "coefficient_of_variation": {
                "definition": "CV = (标准差 / 平均血糖) × 100%",
                "target_value": "<36%",
                "excellent": "<28%",
                "good": "28-36%",
                "poor": ">36%"
              },
              "standard_deviation": {
                "calculation": "血糖读数的标准差",
                "target": "<2.2 mmol/L (<40 mg/dL)",
                "interpretation": "越小表示波动越小"
              },
              "mean_amplitude_of_glycemic_excursions": {
                "abbreviation": "MAGE",
                "definition": "主要血糖波动幅度的平均值",
                "calculation": "复杂算法基于血糖峰谷差"
              }
            },
            "clinical_targets_ada_2025": {
              "primary_metric": "变异系数(CV)",
              "target_population": "所有使用CGM的患者",
              "evidence_level": "B级推荐"
            },
            "factors_influencing": [
              "胰岛素剂量和时机",
              "饮食模式和碳水计数准确性",
              "运动时机和强度",
              "应激和疾病状态",
              "睡眠质量",
              "药物依从性"
            ],
            "health_consequences": {
              "cardiovascular_risk": "高GV与心血管事件风险增加相关",
              "microvascular_complications": "可能加速微血管并发症进展",
              "hypoglycemia_risk": "高变异性增加严重低血糖风险",
              "quality_of_life": "影响患者生活质量和心理健康"
            }
          },
          "improvement_strategies": {
            "insulin_optimization": [
              "基础胰岛素剂量优化",
              "餐时胰岛素与碳水化合物匹配",
              "胰岛素作用时间个体化",
              "闭环系统考虑"
            ],
            "lifestyle_modifications": [
              "规律进餐时间",
              "碳水计数培训",
              "运动前后血糖管理",
              "压力管理技术"
            ],
            "technology_assistance": [
              "CGM实时报警设置",
              "胰岛素泵基础率调整",
              "智能胰岛素笔使用",
              "数据分析软件应用"
            ]
          }
        }
      ],
      "pathological_entities": [
        {
          "id": "PATH_005",
          "name": "糖尿病酮症酸中毒",
          "name_en": "Diabetic Ketoacidosis",
          "type": "acute_complication",
          "category": "急性代谢并发症",
          "description": "糖尿病患者因胰岛素绝对或相对不足导致的急性代谢紊乱综合征",
          "patient_friendly_desc": "DKA是糖尿病的严重急性并发症，需要紧急医疗处理",
          "clinical_significance": "糖尿病急诊最常见原因，病死率5-10%，需要ICU监护治疗",
          "properties": {
            "pathophysiology": {
              "insulin_deficiency": {
                "absolute_deficiency": "1型糖尿病胰岛素治疗中断",
                "relative_deficiency": "2型糖尿病应激状态下胰岛素相对不足",
                "counter_regulatory_hormones": "胰高血糖素、皮质醇、儿茶酚胺、生长激素升高"
              },
              "metabolic_derangements": {
                "hyperglycemia": "葡萄糖利用减少，糖原异生和糖原分解增加",
                "ketogenesis": "脂肪酸β氧化增加，酮体生成增多",
                "acidosis": "β-羟丁酸和乙酰乙酸导致代谢性酸中毒",
                "dehydration": "渗透性利尿导致严重脱水和电解质丢失"
              }
            },
            "diagnostic_criteria": {
              "ada_2025_criteria": {
                "hyperglycemia": "血糖>13.9 mmol/L (>250 mg/dL)",
                "ketonemia": "血酮≥3.0 mmol/L",
                "ketonuria": "尿酮阳性(≥2+)",
                "acidosis": "静脉血气pH<7.30 或 碳酸氢根<15 mEq/L",
                "anion_gap": "阴离子间隙>12 mEq/L"
              },
              "severity_classification": {
                "mild_dka": {
                  "ph": "7.25-7.30",
                  "bicarbonate": "15-18 mEq/L",
                  "mental_status": "清醒",
                  "anion_gap": ">10"
                },
                "moderate_dka": {
                  "ph": "7.00-7.24",
                  "bicarbonate": "10-14 mEq/L",
                  "mental_status": "嗜睡/迟钝",
                  "anion_gap": ">12"
                },
                "severe_dka": {
                  "ph": "<7.00",
                  "bicarbonate": "<10 mEq/L",
                  "mental_status": "昏迷/昏睡",
                  "anion_gap": ">12"
                }
              }
            },
            "precipitating_factors": {
              "most_common": [
                "感染(30-40%)",
                "胰岛素治疗中断或不足",
                "初发糖尿病",
                "心血管事件",
                "其他应激事件"
              ],
              "medications": [
                "糖皮质激素",
                "SGLT2抑制剂",
                "抗精神病药物",
                "免疫抑制剂"
              ],
              "behavioral_factors": [
                "药物依从性差",
                "饮食不当",
                "药物或酒精滥用",
                "心理应激"
              ]
            },
            "clinical_presentation": {
              "early_symptoms": [
                "多尿、多饮、多食",
                "疲劳、乏力",
                "体重下降",
                "视力模糊"
              ],
              "progressive_symptoms": [
                "恶心、呕吐",
                "腹痛",
                "呼吸急促",
                "意识状态改变"
              ],
              "physical_signs": {
                "dehydration": "皮肤干燥、黏膜干燥、眼眶凹陷",
                "kussmaul_breathing": "Kussmaul呼吸(深大呼吸)",
                "fruity_breath": "呼气果味(丙酮味)",
                "altered_consciousness": "从嗜睡到昏迷",
                "cardiovascular": "心动过速、低血压、脉压差小"
              }
            }
          },
          "emergency_management": {
            "initial_assessment": {
              "abcde_approach": {
                "airway": "评估和维护气道通畅",
                "breathing": "氧饱和度监测，必要时给氧",
                "circulation": "血压、心率、毛细血管充盈时间",
                "disability": "神经系统评估，GCS评分",
                "exposure": "全身检查，寻找感染源"
              },
              "immediate_investigations": [
                "血气分析",
                "血糖、血酮",
                "电解质、肾功能",
                "血常规、CRP",
                "心电图",
                "胸片"
              ]
            },
            "fluid_resuscitation": {
              "initial_fluid": {
                "first_choice": "0.9%生理盐水",
                "rate": "15-20 mL/kg/h 第一小时",
                "total_deficit": "通常需要4-6L液体",
                "monitoring": "心率、血压、尿量、CVP"
              },
              "maintenance_fluid": {
                "hours_2_6": "4-14 mL/kg/h",
                "switch_criteria": "血糖降至13.9 mmol/L时",
                "glucose_containing": "5%葡萄糖+0.45%盐水",
                "rate_adjustment": "根据血糖、电解质调整"
              },
              "special_considerations": {
                "heart_failure": "谨慎液体复苏，监测CVP",
                "kidney_disease": "调整液体种类和速度",
                "elderly": "更谨慎的液体管理"
              }
            },
            "insulin_therapy": {
              "iv_insulin_protocol": {
                "loading_dose": "不推荐大剂量负荷",
                "initial_rate": "0.1 U/kg/h 持续静脉泵入",
                "target_reduction": "血糖每小时下降2.8-4.2 mmol/L",
                "adjustment": "根据血糖反应调整剂量"
              },
              "glucose_management": {
                "dual_infusion": "胰岛素+葡萄糖同时输注",
                "target_glucose": "维持血糖8.3-11.1 mmol/L",
                "ketone_clearance": "血酮<0.3 mmol/L时停止胰岛素泵",
                "transition": "过渡到皮下胰岛素方案"
              }
            },
            "electrolyte_management": {
              "potassium": {
                "initial_assessment": "治疗前必须检查血钾",
                "replacement_protocol": {
                  "k_35_55": "20-30 mEq/L 加入液体",
                  "k_30_35": "40-60 mEq/L 加入液体",
                  "k_less_30": "暂停胰岛素，积极补钾"
                },
                "monitoring": "每2-4小时监测血钾"
              },
              "phosphate": {
                "indication": "血磷<1.0 mg/dL",
                "replacement": "磷酸钾 20-30 mEq加入液体",
                "caution": "避免过度补充导致低钙"
              },
              "magnesium": {
                "assessment": "常规检测血镁",
                "replacement": "低镁时给予硫酸镁"
              }
            },
            "bicarbonate_therapy": {
              "controversy": "碳酸氢钠使用存在争议",
              "indications": {
                "severe_acidosis": "pH<6.9或碳酸氢根<5 mEq/L",
                "hyperkalemia": "血钾>6.5 mEq/L",
                "cardiac_instability": "严重心律失常"
              },
              "administration": {
                "dose": "100 mEq 碳酸氢钠加入400mL水",
                "rate": "200 mL/h 静脉输注",
                "monitoring": "每2小时复查血气"
              },
              "complications": [
                "脑水肿风险增加",
                "低钾血症加重",
                "组织缺氧",
                "反弹性代谢性碱中毒"
              ]
            }
          },
          "monitoring_complications": {
            "frequent_monitoring": {
              "vital_signs": "每小时监测",
              "blood_glucose": "每小时",
              "electrolytes": "每2-4小时",
              "blood_gas": "每2-4小时",
              "urine_output": "每小时",
              "neurological_status": "每小时GCS评分"
            },
            "cerebral_edema": {
              "incidence": "0.5-1%成人，2-5%儿童",
              "risk_factors": [
                "初发糖尿病",
                "年龄<25岁",
                "严重脱水",
                "血糖下降过快",
                "过度液体复苏"
              ],
              "clinical_signs": [
                "头痛加重",
                "意识状态恶化",
                "血压升高",
                "心率减慢",
                "瞳孔不等大"
              ],
              "management": {
                "immediate": "甘露醇 1-2 g/kg 静推",
                "alternative": "高渗盐水 5-10 mL/kg",
                "supportive": "限制液体，头部抬高30度",
                "neurosurgical": "必要时脑室引流"
              }
            },
            "other_complications": [
              "肺水肿",
              "急性肾损伤",
              "血栓栓塞",
              "胃麻痹",
              "心律失常"
            ]
          },
          "resolution_criteria": {
            "biochemical_resolution": {
              "glucose": "<11.1 mmol/L",
              "ph": ">7.30",
              "bicarbonate": ">18 mEq/L",
              "anion_gap": "<12 mEq/L",
              "ketones": "血酮<0.3 mmol/L"
            },
            "clinical_resolution": {
              "mental_status": "恢复正常意识",
              "oral_tolerance": "能够进食",
              "hemodynamic_stability": "血流动力学稳定"
            },
            "transition_to_subcutaneous": {
              "timing": "达到分解标准后",
              "overlap": "皮下胰岛素给药后2小时停IV",
              "regimen": "根据既往用量和当前需求"
            }
          },
          "prevention_strategies": {
            "patient_education": [
              "胰岛素不能随意停用",
              "病期管理规则",
              "血糖和酮体监测",
              "早期预警症状识别",
              "何时寻求医疗帮助"
            ],
            "healthcare_provider": [
              "规律随访和监测",
              "感染预防和早期治疗",
              "药物调整指导",
              "心理支持和依从性改善"
            ]
          }
        },
        {
          "id": "PATH_006",
          "name": "高血糖高渗状态",
          "name_en": "Hyperosmolar Hyperglycemic State",
          "type": "acute_complication",
          "category": "急性代谢并发症",
          "description": "2型糖尿病患者的严重急性并发症，以极度高血糖和高渗透压为特征",
          "patient_friendly_desc": "HHS是2型糖尿病的严重急性并发症，需要立即医疗处理",
          "clinical_significance": "病死率10-20%，多见于老年患者，需要ICU监护治疗",
          "properties": {
            "pathophysiology": {
              "insulin_resistance": "胰岛素相对不足，但足以抑制脂解",
              "hyperglycemia": "极度高血糖(通常>33.3 mmol/L)",
              "hyperosmolality": "有效渗透压>320 mOsm/kg",
              "dehydration": "严重脱水，通常丢失体重10-15%",
              "minimal_ketosis": "酮体生成轻微，pH通常>7.30"
            },
            "diagnostic_criteria": {
              "hyperglycemia": "血糖>33.3 mmol/L (>600 mg/dL)",
              "effective_osmolality": ">320 mOsm/kg H2O",
              "ph": ">7.30",
              "bicarbonate": ">18 mEq/L",
              "minimal_ketones": "血酮<3 mmol/L，尿酮阴性或微量",
              "altered_consciousness": "不同程度的意识改变"
            },
            "precipitating_factors": {
              "most_common": [
                "感染(50-60%)",
                "心血管事件",
                "脑血管意外",
                "药物不依从",
                "其他急性疾病"
              ],
              "medications": [
                "糖皮质激素",
                "利尿剂",
                "β受体阻滞剂",
                "钙通道阻滞剂"
              ],
              "procedures": [
                "透析",
                "肠内或肠外营养",
                "外科手术"
              ]
            },
            "clinical_presentation": {
              "gradual_onset": "通常数天至数周逐渐起病",
              "neurological_symptoms": [
                "意识模糊",
                "定向障碍",
                "幻觉",
                "局灶性神经功能缺损",
                "癫痫发作",
                "昏迷"
              ],
              "physical_signs": {
                "severe_dehydration": "皮肤弹性极差，黏膜干燥",
                "hypotension": "低血压，体位性低血压",
                "tachycardia": "心动过速",
                "hyperthermia": "发热常见",
                "absent_kussmaul": "无Kussmaul呼吸"
              }
            }
          },
          "emergency_management": {
            "initial_resuscitation": {
              "fluid_therapy": {
                "initial_fluid": "0.9%生理盐水",
                "rate": "15-20 mL/kg/h 第一小时",
                "subsequent": "根据血流动力学状态调整",
                "total_deficit": "通常需要8-12L液体",
                "monitoring": "CVP、尿量、血压"
              },
              "electrolyte_replacement": {
                "potassium": "与DKA相似的补充策略",
                "sodium": "谨慎纠正，避免过快",
                "phosphate": "必要时补充",
                "magnesium": "常规监测和补充"
              }
            },
            "insulin_therapy": {
              "initial_approach": "液体复苏优先于胰岛素",
              "insulin_dosing": {
                "loading_dose": "不推荐负荷剂量",
                "maintenance": "0.05-0.1 U/kg/h",
                "adjustment": "根据血糖下降速度调整"
              },
              "glucose_targets": {
                "hourly_reduction": "2.8-4.2 mmol/L/h",
                "switch_point": "血糖降至16.7 mmol/L",
                "maintenance_target": "11.1-16.7 mmol/L"
              }
            },
            "osmolality_management": {
              "calculation": "2×[Na+] + 葡萄糖/18 + BUN/2.8",
              "correction_rate": "不超过3-8 mOsm/kg/h",
              "target_osmolality": "<320 mOsm/kg",
              "monitoring": "每4-6小时计算"
            }
          },
          "special_considerations": {
            "elderly_patients": {
              "increased_risk": "年龄>65岁风险显著增加",
              "comorbidities": "常伴有心肾疾病",
              "fluid_management": "更加谨慎的液体复苏",
              "monitoring": "密切监测心肺功能"
            },
            "neurological_monitoring": {
              "consciousness_level": "GCS评分每小时",
              "focal_deficits": "可能模拟卒中",
              "seizure_management": "抗癫痫药物使用",
              "cerebral_edema": "虽少见但需警惕"
            }
          }
        },
        {
          "id": "PATH_007",
          "name": "严重低血糖症",
          "name_en": "Severe Hypoglycemia",
          "type": "acute_complication",
          "category": "急性代谢并发症",
          "description": "血糖过低导致的急性医疗紧急状态，可危及生命",
          "patient_friendly_desc": "严重低血糖是血糖过低的紧急状况，需要立即治疗",
          "clinical_significance": "糖尿病患者最常见的急性并发症，可导致昏迷、脑损伤甚至死亡",
          "properties": {
            "definitions": {
              "biochemical_hypoglycemia": "血糖<3.9 mmol/L (<70 mg/dL)",
              "clinically_significant": "血糖<3.0 mmol/L (<54 mg/dL)",
              "severe_hypoglycemia": "需要他人协助的低血糖事件",
              "nocturnal_hypoglycemia": "睡眠期间发生的低血糖"
            },
            "pathophysiology": {
              "glucose_counterregulation": {
                "first_defense": "胰岛素分泌减少(4.4-4.7 mmol/L)",
                "second_defense": "胰高血糖素分泌(3.6-3.9 mmol/L)",
                "third_defense": "肾上腺素分泌(2.8-3.1 mmol/L)",
                "fourth_defense": "皮质醇、生长激素(2.8 mmol/L)"
              },
              "impaired_awareness": {
                "hypoglycemia_unawareness": "反复低血糖导致症状感知能力下降",
                "defective_counterregulation": "胰高血糖素和肾上腺素反应受损",
                "risk_factors": ["病程长", "严格血糖控制", "自主神经病变"]
              }
            },
            "clinical_presentation": {
              "autonomic_symptoms": {
                "adrenergic": ["心悸", "震颤", "出汗", "焦虑"],
                "cholinergic": ["饥饿感", "恶心", "出汗"],
                "onset": "血糖2.8-3.9 mmol/L时出现"
              },
              "neuroglycopenic_symptoms": {
                "early": ["注意力不集中", "思维迟缓", "言语不清"],
                "late": ["意识模糊", "行为异常", "癫痫发作", "昏迷"],
                "onset": "血糖<2.8 mmol/L时明显"
              },
              "nocturnal_hypoglycemia": [
                "夜间噩梦、盗汗",
                "晨起头痛",
                "晨起血糖反弹性升高",
                "睡眠质量差"
              ]
            },
            "risk_factors": {
              "medication_related": [
                "胰岛素剂量过大",
                "磺脲类药物",
                "格列奈类药物",
                "药物时机不当"
              ],
              "behavioral_factors": [
                "进食不足或延迟",
                "运动量增加未调整治疗",
                "酒精摄入",
                "呕吐或腹泻"
              ],
              "physiological_factors": [
                "肾功能不全",
                "肝功能不全",
                "内分泌疾病",
                "胃轻瘫"
              ],
              "iatrogenic_factors": [
                "严格血糖控制",
                "频繁调整药物",
                "不恰当的治疗目标"
              ]
            }
          },
          "emergency_management": {
            "conscious_patient": {
              "rule_of_15": {
                "step1": "15g快速作用碳水化合物",
                "step2": "等待15分钟",
                "step3": "重新检测血糖",
                "step4": "如仍<3.9 mmol/L重复治疗"
              },
              "glucose_sources": [
                "葡萄糖片 4-5片(15-20g)",
                "果汁 150mL",
                "糖果 15-20g",
                "蜂蜜 1大勺"
              ],
              "follow_up_treatment": {
                "complex_carb": "15-30g复合碳水化合物",
                "timing": "快速糖源后15-20分钟",
                "examples": "面包、饼干、水果"
              }
            },
            "unconscious_patient": {
              "prehospital": {
                "glucagon": "1mg 肌注或皮下注射",
                "alternative": "葡萄糖凝胶 口腔黏膜",
                "positioning": "侧卧位，防止误吸",
                "monitoring": "意识和呼吸状态"
              },
              "hospital_treatment": {
                "iv_glucose": {
                  "initial": "25-50g 50%葡萄糖静推",
                  "alternative": "100-200mL 10%葡萄糖",
                  "pediatric": "0.5-1g/kg 10%葡萄糖"
                },
                "continuous_infusion": {
                  "indication": "反复低血糖或长效药物",
                  "solution": "5-10%葡萄糖溶液",
                  "rate": "根据血糖监测调整"
                }
              }
            },
            "refractory_hypoglycemia": {
              "octreotide": {
                "indication": "磺脲类药物过量",
                "dosage": "50-100μg 皮下 q6-8h",
                "mechanism": "抑制胰岛素分泌"
              },
              "diazoxide": {
                "indication": "持续性高胰岛素血症",
                "dosage": "3-8 mg/kg/day 口服",
                "monitoring": "血压、水钠潴留"
              }
            }
          },
          "prevention_strategies": {
            "patient_education": {
              "recognition": "早期症状识别和自我处理",
              "treatment": "15法则的正确应用",
              "prevention": "进餐时机、运动调整、酒精限制",
              "monitoring": "血糖监测频率和时机",
              "emergency_plan": "家属教育和应急处理"
            },
            "medication_adjustment": {
              "insulin_modification": [
                "剂量减少10-20%",
                "注射时机调整",
                "胰岛素类型更换",
                "基础-餐时比例调整"
              ],
              "oral_medication": [
                "磺脲类减量或停用",
                "改用低血糖风险小的药物",
                "用药时机调整"
              ]
            },
            "cgm_utilization": {
              "real_time_alerts": "低血糖预警设置",
              "trend_monitoring": "血糖下降趋势识别",
              "pattern_analysis": "识别低血糖好发时间",
              "family_sharing": "远程监测和报警"
            }
          }
        },
        {
          "id": "PATH_008",
          "name": "妊娠糖尿病",
          "name_en": "Gestational Diabetes Mellitus",
          "type": "pregnancy_disorder",
          "category": "妊娠期糖尿病",
          "description": "妊娠期首次发现或发生的糖代谢异常，对母婴健康都有重要影响",
          "patient_friendly_desc": "妊娠糖尿病是怀孕期间发生的血糖异常，需要特别管理以保护母婴健康",
          "clinical_significance": "影响6-9%的妊娠，增加母婴并发症风险，需要多学科协作管理",
          "properties": {
            "pathophysiology": {
              "insulin_resistance": {
                "mechanism": "胎盘激素导致胰岛素抵抗增加",
                "progression": "妊娠中晚期胰岛素抵抗进行性加重",
                "hormonal_factors": ["人胎盘催乳素", "皮质醇", "胎盘生长激素", "孕酮"],
                "compensatory_response": "正常情况下胰岛素分泌增加2-3倍"
              },
              "risk_factors": {
                "maternal_factors": [
                  "年龄≥25岁",
                  "肥胖(BMI≥30)",
                  "糖尿病家族史",
                  "既往GDM史",
                  "多囊卵巢综合征",
                  "种族因素(亚洲、西班牙、非洲裔)"
                ],
                "obstetric_factors": [
                  "既往巨大儿分娩史",
                  "既往不良妊娠结局",
                  "羊水过多",
                  "多胎妊娠"
                ]
              }
            },
            "diagnostic_criteria": {
              "iadpsg_who_2013": {
                "screening_timing": "24-28周妊娠期间",
                "ogtt_procedure": "75g口服葡萄糖耐量试验",
                "diagnostic_thresholds": {
                  "fasting": "≥5.1 mmol/L (92 mg/dL)",
                  "1_hour": "≥10.0 mmol/L (180 mg/dL)", 
                  "2_hour": "≥8.5 mmol/L (153 mg/dL)"
                },
                "diagnosis": "任意一项达到或超过阈值即可诊断"
              },
              "high_risk_early_screening": {
                "timing": "妊娠早期(12-16周)",
                "indications": [
                  "既往GDM史",
                  "BMI≥35",
                  "强糖尿病家族史",
                  "既往巨大儿史"
                ],
                "methods": "空腹血糖或HbA1c或OGTT"
              },
              "differential_diagnosis": {
                "pregestational_diabetes": {
                  "criteria": [
                    "妊娠早期HbA1c≥6.5%",
                    "空腹血糖≥7.0 mmol/L",
                    "随机血糖≥11.1 mmol/L+症状"
                  ],
                  "management": "按既有糖尿病管理"
                }
              }
            },
            "maternal_complications": {
              "acute_complications": [
                "妊娠期高血压疾病",
                "羊水过多",
                "泌尿系感染",
                "酮症酸中毒(罕见)"
              ],
              "delivery_complications": [
                "剖宫产率增加",
                "肩难产",
                "产道损伤",
                "产后出血"
              ],
              "long_term_risks": {
                "type2_diabetes": "产后5-10年内50-90%发生2型糖尿病",
                "metabolic_syndrome": "心血管疾病风险增加",
                "subsequent_pregnancy": "再次GDM风险50-90%"
              }
            },
            "fetal_neonatal_complications": {
              "macrosomia": {
                "definition": "出生体重>4000g或>90百分位数",
                "incidence": "15-45%GDM孕妇",
                "mechanism": "胎儿高胰岛素血症促进脂肪合成",
                "consequences": "肩难产、产伤、剖宫产"
              },
              "neonatal_complications": [
                "新生儿低血糖",
                "呼吸窘迫综合征",
                "低钙血症",
                "红细胞增多症",
                "黄疸"
              ],
              "long_term_offspring_risks": [
                "儿童期肥胖",
                "青春期糖尿病前期",
                "成年期2型糖尿病",
                "心血管疾病"
              ]
            }
          },
          "management_strategies": {
            "lifestyle_interventions": {
              "medical_nutrition_therapy": {
                "caloric_requirements": {
                  "total_calories": "25-35 kcal/kg 孕前理想体重",
                  "underweight": "36-40 kcal/kg",
                  "normal_weight": "30-32 kcal/kg", 
                  "overweight": "25-30 kcal/kg",
                  "obese": "12-14 kcal/kg"
                },
                "macronutrient_distribution": {
                  "carbohydrates": "40-45%总热量，分配至3正餐+2-4加餐",
                  "proteins": "20-25%总热量，优质蛋白",
                  "fats": "30-35%总热量，限制饱和脂肪"
                },
                "meal_planning": {
                  "carb_counting": "严格碳水化合物计数",
                  "meal_timing": "规律进餐，避免长时间空腹",
                  "bedtime_snack": "睡前含蛋白质的加餐",
                  "avoid_simple_sugars": "限制精制糖和含糖饮料"
                }
              },
              "physical_activity": {
                "recommendations": "中等强度活动30分钟/天",
                "safe_activities": ["步行", "游泳", "孕妇瑜伽", "固定自行车"],
                "contraindications": [
                  "胎盘前置",
                  "早产史",
                  "妊娠期高血压",
                  "胎膜早破"
                ],
                "monitoring": "运动前后血糖监测"
              }
            },
            "glucose_monitoring": {
              "targets": {
                "fasting": "<5.3 mmol/L (95 mg/dL)",
                "1h_postprandial": "<7.8 mmol/L (140 mg/dL)",
                "2h_postprandial": "<6.7 mmol/L (120 mg/dL)"
              },
              "frequency": {
                "initial": "每日4次(空腹+三餐后1小时)",
                "stable": "可减少至每日2-3次",
                "adjustment_period": "药物调整时增加监测"
              },
              "cgm_considerations": {
                "indications": "多次胰岛素注射患者",
                "benefits": "减少指尖采血，改善依从性",
                "limitations": "妊娠期准确性数据有限",
                "targets": "修改为妊娠期特异性目标"
              }
            },
            "pharmacological_treatment": {
              "insulin_therapy": {
                "indications": [
                  "生活方式干预1-2周后血糖不达标",
                  "空腹血糖≥5.8 mmol/L",
                  "餐后血糖持续超标",
                  "胎儿生长异常"
                ],
                "insulin_types": {
                  "safe_options": ["人胰岛素", "门冬胰岛素", "赖脯胰岛素"],
                  "avoid": "长效胰岛素类似物数据有限",
                  "preferred_regimen": "餐时胰岛素±基础胰岛素"
                },
                "dosing": {
                  "starting_dose": "0.7-1.0 U/kg/day",
                  "distribution": "50%基础，50%餐时",
                  "adjustment": "根据血糖监测结果调整",
                  "third_trimester": "需求量可增加50-100%"
                }
              },
              "oral_medications": {
                "metformin": {
                  "pregnancy_category": "B类",
                  "evidence": "某些研究支持安全性",
                  "considerations": "穿过胎盘，长期影响未明",
                  "usage": "二线选择，需充分咨询"
                },
                "glyburide": {
                  "pregnancy_category": "B类", 
                  "evidence": "较多妊娠期使用数据",
                  "limitations": "可能穿过胎盘",
                  "usage": "胰岛素不可接受时考虑"
                },
                "avoid": [
                  "SGLT2抑制剂",
                  "GLP-1受体激动剂",
                  "DPP-4抑制剂"
                ]
              }
            },
            "fetal_surveillance": {
              "growth_monitoring": {
                "ultrasound_frequency": "每4周评估胎儿生长",
                "parameters": ["估计胎儿体重", "腹围", "羊水量"],
                "macrosomia_detection": "EFW>90百分位数或AC>95百分位数",
                "oligohydramnios_polyhydramnios": "羊水量异常评估"
              },
              "antepartum_testing": {
                "timing": "32-36周开始",
                "methods": ["胎心监护", "生物物理评分", "脐动脉多普勒"],
                "frequency": "每周1-2次",
                "indications": "血糖控制差、胎儿生长异常、合并症"
              }
            },
            "delivery_planning": {
              "timing": {
                "well_controlled": "39-40周",
                "poor_control": "37-39周",
                "macrosomia": "考虑38-39周",
                "maternal_complications": "个体化决策"
              },
              "mode_of_delivery": {
                "vaginal_delivery": "首选自然分娩",
                "cesarean_indications": [
                  "EFW>4500g",
                  "既往肩难产史",
                  "产科指征",
                  "母体疾病"
                ]
              },
              "peripartum_management": {
                "glucose_monitoring": "分娩期间每1-2小时监测",
                "insulin_adjustment": "分娩时停用胰岛素",
                "target_glucose": "4.0-7.0 mmol/L",
                "neonatal_preparation": "儿科医生在场"
              }
            }
          },
          "postpartum_care": {
            "immediate_postpartum": {
              "glucose_monitoring": "产后24-72小时监测",
              "insulin_cessation": "通常无需继续胰岛素",
              "breastfeeding": {
                "encouragement": "积极鼓励母乳喂养",
                "benefits": "降低母亲糖尿病风险，有利婴儿代谢",
                "nutrition": "哺乳期营养指导",
                "medication": "哺乳期安全用药"
              }
            },
            "long_term_follow_up": {
              "diabetes_screening": {
                "timing": "产后6-12周",
                "method": "75g OGTT",
                "interpretation": "WHO糖尿病诊断标准",
                "subsequent": "每1-3年筛查"
              },
              "lifestyle_counseling": {
                "weight_management": "恢复孕前体重",
                "healthy_diet": "持续健康饮食模式", 
                "physical_activity": "规律运动习惯",
                "smoking_cessation": "戒烟支持"
              },
              "contraception": {
                "family_planning": "生育间隔咨询",
                "contraceptive_methods": "安全有效的避孕方法",
                "preconception_counseling": "再次妊娠前咨询"
              }
            }
          },
          "special_considerations": {
            "cultural_dietary_factors": {
              "ethnic_variations": "不同种族饮食模式适应",
              "cultural_foods": "传统食物的血糖影响评估",
              "family_involvement": "家庭成员饮食教育",
              "religious_considerations": "宗教饮食要求适应"
            },
            "psychosocial_support": {
              "anxiety_management": "妊娠期焦虑和担忧处理",
              "family_support": "配偶和家庭支持系统",
              "peer_support": "GDM患者支持小组",
              "mental_health": "产前产后抑郁筛查"
            },
            "healthcare_coordination": {
              "multidisciplinary_team": [
                "产科医生",
                "内分泌科医生", 
                "营养师",
                "糖尿病教育者",
                "新生儿科医生"
              ],
              "communication": "团队间有效沟通机制",
              "care_transitions": "产前产后护理衔接"
            }
          }
        },
        {
          "id": "PATH_003",
          "name": "成人潜伏性自身免疫糖尿病",
          "name_en": "Latent Autoimmune Diabetes in Adults",
          "type": "disease",
          "category": "特殊类型糖尿病",
          "description": "成人发病的进展缓慢的自身免疫性糖尿病，介于1型和2型糖尿病之间",
          "patient_friendly_desc": "LADA是一种特殊的糖尿病类型，起病像2型但实际是缓慢进展的1型糖尿病",
          "clinical_significance": "约占成人糖尿病的5-10%，ADA 2025强调早期识别的重要性",
          "properties": {
            "ada_2025_diagnostic_criteria": {
              "age_of_onset": "≥30岁",
              "autoantibody_positive": "至少一种胰岛自身抗体阳性",
              "initial_insulin_independence": "诊断后至少6个月不需要胰岛素",
              "c_peptide_levels": "通常保存但逐渐下降"
            },
            "autoantibody_panel": {
              "gad_antibodies": {
                "name": "谷氨酸脱羧酶抗体",
                "sensitivity": "70-80%",
                "specificity": ">95%",
                "most_common": "LADA最常见的抗体"
              },
              "ia2_antibodies": {
                "name": "蛋白酪氨酸磷酸酶抗体",
                "sensitivity": "50-60%",
                "prognostic_value": "预测胰岛素需求时间"
              },
              "znt8_antibodies": {
                "name": "锌转运蛋白8抗体",
                "sensitivity": "20-30%",
                "additional_value": "提高诊断敏感性"
              }
            },
            "clinical_phenotypes": {
              "classic_lada": {
                "characteristics": "GAD抗体高滴度，快速进展",
                "insulin_requirement": "1-2年内需要胰岛素"
              },
              "slowly_progressive": {
                "characteristics": "GAD抗体低滴度，缓慢进展",
                "insulin_requirement": "5-10年后需要胰岛素"
              }
            },
            "differential_diagnosis": {
              "from_type1": [
                "发病年龄较大",
                "进展相对缓慢",
                "可能有代谢综合征特征"
              ],
              "from_type2": [
                "自身抗体阳性",
                "通常不肥胖",
                "对口服药反应差"
              ]
            }
          },
          "ada_2025_management_updates": {
            "early_identification": {
              "screening_indications": [
                "成人新诊断糖尿病且BMI<25",
                "家族史阳性",
                "其他自身免疫病史",
                "口服药物早期失效"
              ],
              "testing_strategy": "GAD抗体作为首选筛查指标"
            },
            "treatment_approach": {
              "initial_management": {
                "lifestyle_interventions": "标准医学营养治疗和运动",
                "metformin_consideration": "可短期使用，但效果有限",
                "sulfonylurea_avoidance": "避免使用，可能加速β细胞衰竭"
              },
              "insulin_therapy": {
                "timing": "基于C肽水平和血糖控制情况",
                "early_insulin": "可能延缓β细胞功能衰退",
                "regimen": "从基础胰岛素开始，逐步强化"
              },
              "novel_therapies": {
                "glp1_agonists": "可能有β细胞保护作用",
                "immunotherapy": "研究阶段，teplizumab等"
              }
            }
          },
          "monitoring_strategy": {
            "c_peptide_tracking": "定期监测评估β细胞功能",
            "autoantibody_followup": "不建议重复检测",
            "complications_screening": "同1型糖尿病标准"
          }
        },
        {
          "id": "PATH_004",
          "name": "单基因糖尿病",
          "name_en": "Monogenic Diabetes",
          "type": "disease",
          "category": "遗传性糖尿病",
          "description": "由单个基因突变引起的糖尿病，包括MODY、新生儿糖尿病等类型",
          "patient_friendly_desc": "单基因糖尿病是由遗传基因异常直接导致的糖尿病，有明确的家族遗传模式",
          "clinical_significance": "ADA 2025强调精准诊断对治疗选择和家族咨询的重要性",
          "properties": {
            "mody_subtypes": {
              "mody1_hnf4a": {
                "gene": "HNF4A",
                "prevalence": "5-10% of MODY",
                "characteristics": "对磺脲类敏感，可能有巨大胎儿史",
                "treatment": "磺脲类一线选择"
              },
              "mody2_gck": {
                "gene": "GCK (葡萄糖激酶)",
                "prevalence": "30-60% of MODY",
                "characteristics": "轻度空腹高血糖，HbA1c通常<7.5%",
                "treatment": "通常只需生活方式干预"
              },
              "mody3_hnf1a": {
                "gene": "HNF1A",
                "prevalence": "30-65% of MODY",
                "characteristics": "对磺脲类极其敏感，可能有肾囊肿",
                "treatment": "磺脲类首选，避免胰岛素"
              },
              "mody5_hnf1b": {
                "gene": "HNF1B",
                "prevalence": "5% of MODY",
                "characteristics": "肾脏和胰腺联合异常",
                "treatment": "通常需要胰岛素"
              }
            },
            "neonatal_diabetes": {
              "transient_nnd": {
                "genetics": "6q24异常或母体印记缺陷",
                "clinical_course": "通常在6个月内缓解，青春期可能复发",
                "treatment": "急性期胰岛素，缓解期监测"
              },
              "permanent_nnd": {
                "common_genes": ["KCNJ11", "ABCC8", "INS"],
                "sulfonylurea_responsive": "KATP通道突变患者",
                "treatment": "基因型指导的个体化治疗"
              }
            },
            "ada_2025_diagnostic_approach": {
              "clinical_suspicion_criteria": [
                "糖尿病家族史3代连续",
                "25岁前诊断且不肥胖",
                "轻度糖尿病但无自身抗体",
                "胰腺外表现（肾囊肿等）"
              ],
              "genetic_testing_indications": "符合临床特征的患者",
              "testing_strategy": "基于表型的分步检测方法"
            }
          },
          "precision_medicine_implications": {
            "pharmacogenomics": {
              "sulfonylurea_response": "HNF1A/HNF4A突变患者超敏感",
              "metformin_response": "GCK突变患者通常无效",
              "insulin_requirement": "基因型决定胰岛素需求"
            },
            "family_counseling": {
              "inheritance_patterns": "常染色体显性遗传为主",
              "genetic_counseling": "家族成员筛查和生育指导",
              "predictive_testing": "无症状家族成员的预测性检测"
            }
          }
        }
      ],
      "clinical_entities": [
        {
          "id": "DRUG_003",
          "name": "GLP-1受体激动剂类",
          "name_en": "GLP-1 Receptor Agonists",
          "type": "medication_class",
          "category": "肠促胰素类降糖药",
          "description": "模拟天然GLP-1激素作用的降糖药物，具有多重代谢益处",
          "patient_friendly_desc": "GLP-1受体激动剂模拟肠道激素，不仅降血糖，还能减重和保护心血管",
          "clinical_significance": "ADA 2025推荐的2型糖尿病重要治疗选择，具有心肾保护作用",
          "properties": {
            "mechanism_of_action": {
              "primary_effects": [
                "葡萄糖依赖性促进胰岛素分泌",
                "抑制胰高血糖素分泌",
                "延缓胃排空",
                "增加饱腹感，减少食物摄入"
              ],
              "secondary_effects": [
                "改善β细胞功能",
                "可能促进β细胞增殖",
                "抗炎作用",
                "改善脂代谢"
              ]
            },
            "drug_classification": {
              "short_acting": {
                "examples": ["艾塞那肽", "利拉鲁肽"],
                "dosing_frequency": "每日1-2次",
                "duration": "12-24小时"
              },
              "long_acting": {
                "examples": ["度拉糖肽", "司马鲁肽", "达格列净"],
                "dosing_frequency": "每周1次",
                "duration": "7天"
              },
              "oral_formulations": {
                "example": "口服司马鲁肽",
                "advantages": "避免注射，提高依从性",
                "limitations": "严格服药要求"
              }
            },
            "ada_2025_recommendations": {
              "first_line_indications": [
                "2型糖尿病伴心血管疾病",
                "2型糖尿病伴慢性肾病",
                "需要减重的2型糖尿病患者"
              ],
              "evidence_level": "A级推荐",
              "combination_therapy": "与二甲双胍联用为标准方案"
            },
            "cardiovascular_outcomes": {
              "cvot_trials": {
                "leader_trial": {
                  "drug": "利拉鲁肽",
                  "result": "心血管死亡降低22%",
                  "population": "高心血管风险患者"
                },
                "sustain6_trial": {
                  "drug": "司马鲁肽",
                  "result": "主要心血管事件降低26%",
                  "additional_benefit": "卒中风险显著降低"
                },
                "rewind_trial": {
                  "drug": "度拉糖肽",
                  "result": "心血管事件降低12%",
                  "significance": "包含低心血管风险患者"
                }
              },
              "mechanism_of_cv_protection": [
                "改善内皮功能",
                "抗动脉粥样硬化",
                "降血压作用",
                "抗炎效应"
              ]
            },
            "renal_outcomes": {
              "kidney_protection": [
                "降低蛋白尿",
                "延缓eGFR下降",
                "减少肾病进展风险"
              ],
              "flow_trial": {
                "drug": "司马鲁肽",
                "primary_endpoint": "肾脏复合终点降低24%",
                "significance": "首个证明肾脏保护的GLP-1RA"
              }
            },
            "weight_management": {
              "weight_loss_magnitude": {
                "average_reduction": "3-8kg",
                "dose_dependent": "高剂量效果更显著",
                "sustained_effect": "长期维持减重效果"
              },
              "obesity_indications": {
                "high_dose_semaglutide": "2.4mg周制剂用于肥胖治疗",
                "tirzepatide": "双重激动剂，减重效果更强"
              }
            },
            "side_effects_profile": {
              "gastrointestinal": {
                "incidence": "20-40%患者",
                "symptoms": ["恶心", "呕吐", "腹泻", "便秘"],
                "management": "从低剂量开始，缓慢调整",
                "duration": "通常4-8周内改善"
              },
              "serious_adverse_events": {
                "pancreatitis": {
                  "incidence": "罕见(<0.1%)",
                  "monitoring": "腹痛、血淀粉酶升高时停药",
                  "contraindication": "胰腺炎病史"
                },
                "thyroid_concerns": {
                  "animal_data": "啮齿动物甲状腺C细胞瘤",
                  "human_relevance": "临床意义不明",
                  "contraindication": "MTC或MEN2综合征"
                }
              }
            },
            "contraindications_precautions": {
              "absolute_contraindications": [
                "1型糖尿病",
                "糖尿病酮症酸中毒",
                "严重胃肠道疾病",
                "甲状腺髓样癌病史/家族史",
                "MEN2综合征"
              ],
              "relative_contraindications": [
                "既往胰腺炎",
                "严重肾功能不全",
                "妊娠和哺乳期",
                "年龄<18岁"
              ]
            },
            "clinical_monitoring": {
              "baseline_assessment": [
                "胰腺炎病史",
                "胃肠道疾病史",
                "甲状腺疾病筛查",
                "肾功能评估"
              ],
              "ongoing_monitoring": [
                "血糖控制效果",
                "体重变化",
                "胃肠道耐受性",
                "肾功能变化"
              ]
            }
          },
          "prescribing_considerations": {
            "patient_selection": {
              "ideal_candidates": [
                "需要心血管保护的患者",
                "超重肥胖患者",
                "慢性肾病患者",
                "注重生活质量的患者"
              ],
              "less_suitable": [
                "胃肠道疾病患者",
                "经济条件限制患者",
                "不能接受注射的患者"
              ]
            },
            "cost_effectiveness": {
              "high_acquisition_cost": "月费用较高",
              "long_term_value": "心血管获益可能具有成本效益",
              "insurance_coverage": "多数保险覆盖，需要预授权"
            }
          }
        },
        {
          "id": "DRUG_004",
          "name": "SGLT2抑制剂类",
          "name_en": "SGLT2 Inhibitors",
          "type": "medication_class",
          "category": "钠葡萄糖共转运蛋白2抑制剂",
          "description": "通过抑制肾脏葡萄糖重吸收降血糖的药物，具有心肾保护作用",
          "patient_friendly_desc": "SGLT2抑制剂通过肾脏排出多余的糖分来降血糖，同时保护心脏和肾脏",
          "clinical_significance": "ADA 2025强烈推荐的心肾保护药物，改变了2型糖尿病治疗格局",
          "properties": {
            "mechanism_of_action": {
              "primary_mechanism": "抑制肾脏近曲小管SGLT2，减少葡萄糖重吸收",
              "glucose_elimination": "每日排出60-80g葡萄糖",
              "calorie_loss": "约240-320千卡/日",
              "insulin_independent": "不依赖胰岛素作用"
            },
            "available_agents": {
              "canagliflozin": {
                "brand_name": "怡可安",
                "dosing": "100-300mg每日1次",
                "special_features": "轻度SGLT1抑制作用"
              },
              "dapagliflozin": {
                "brand_name": "达格列净",
                "dosing": "5-10mg每日1次",
                "indications": "糖尿病、心衰、慢性肾病"
              },
              "empagliflozin": {
                "brand_name": "恩格列净",
                "dosing": "10-25mg每日1次",
                "landmark_trial": "EMPA-REG OUTCOME"
              },
              "ertugliflozin": {
                "brand_name": "艾托格列净",
                "dosing": "5-15mg每日1次",
                "combination": "常与其他降糖药联合"
              }
            },
            "cardiovascular_benefits": {
              "empa_reg_outcome": {
                "primary_endpoint": "心血管死亡降低38%",
                "heart_failure_hospitalization": "降低35%",
                "all_cause_mortality": "降低32%"
              },
              "canvas_program": {
                "drug": "卡格列净",
                "cardiovascular_benefit": "心血管事件降低14%",
                "concern": "截肢风险轻度增加"
              },
              "declare_timi58": {
                "drug": "达格列净",
                "heart_failure_benefit": "心衰住院风险降低27%",
                "safety_profile": "良好的安全性"
              }
            },
            "renal_protection": {
              "credence_trial": {
                "drug": "卡格列净",
                "population": "2型糖尿病肾病",
                "primary_outcome": "肾脏复合终点降低30%"
              },
              "dapa_ckd_trial": {
                "drug": "达格列净",
                "population": "慢性肾病（包括非糖尿病）",
                "outcome": "肾功能恶化风险降低39%"
              },
              "kidney_protection_mechanisms": [
                "降低肾小球内压",
                "减少蛋白尿",
                "抗炎和抗纤维化",
                "改善肾脏血流动力学"
              ]
            },
            "heart_failure_benefits": {
              "dapa_hf_trial": {
                "population": "射血分数降低的心衰（伴或不伴糖尿病）",
                "primary_outcome": "心血管死亡或心衰恶化降低26%"
              },
              "emperor_reduced": {
                "drug": "恩格列净",
                "population": "HFrEF",
                "outcome": "主要终点降低25%"
              },
              "mechanism_in_heart_failure": [
                "利尿作用",
                "降低前负荷",
                "改善心肌代谢",
                "抗炎作用"
              ]
            },
            "metabolic_effects": {
              "weight_loss": {
                "magnitude": "平均2-4kg",
                "mechanism": "热量丢失和轻度利尿",
                "sustained": "长期维持"
              },
              "blood_pressure": {
                "systolic_reduction": "2-6 mmHg",
                "diastolic_reduction": "1-3 mmHg",
                "mechanism": "渗透性利尿和血管作用"
              },
              "uric_acid": {
                "effect": "血尿酸水平降低",
                "mechanism": "增加尿酸排泄"
              }
            },
            "adverse_effects": {
              "genitourinary_infections": {
                "genital_mycotic_infections": {
                  "incidence": "女性10-15%，男性5-8%",
                  "management": "抗真菌治疗，严重者停药",
                  "prevention": "个人卫生，高危患者预防"
                },
                "urinary_tract_infections": {
                  "incidence": "轻度增加",
                  "monitoring": "定期尿检"
                }
              },
              "volume_depletion": {
                "risk_factors": "年龄>75岁，利尿剂使用，低血压",
                "symptoms": "头晕、乏力、直立性低血压",
                "management": "监测血容量状态，调整其他药物"
              },
              "diabetic_ketoacidosis": {
                "euglycemic_dka": "血糖正常或轻度升高的DKA",
                "risk_factors": "胰岛素缺乏、感染、手术、低碳水饮食",
                "prevention": "病期停药，监测酮体"
              },
              "amputation_risk": {
                "association": "主要见于卡格列净",
                "mechanism": "可能与血管因素相关",
                "monitoring": "足部检查，高危患者谨慎使用"
              }
            },
            "contraindications": {
              "absolute": [
                "1型糖尿病（除特殊适应症）",
                "严重肾功能不全（eGFR<30）",
                "透析患者"
              ],
              "relative": [
                "复发性生殖道感染",
                "血容量不足",
                "年龄>85岁"
              ]
            }
          },
          "ada_2025_positioning": {
            "first_line_consideration": [
              "确诊心血管疾病",
              "慢性肾病（eGFR 30-60或蛋白尿）",
              "心力衰竭"
            ],
            "evidence_strength": "A级推荐",
            "combination_strategies": "与二甲双胍和/或GLP-1RA联用"
          },
          "clinical_implementation": {
            "patient_counseling": [
              "生殖道感染风险和预防",
              "充分水分摄入的重要性",
              "病期停药的必要性",
              "足部护理重要性"
            ],
            "monitoring_requirements": [
              "肾功能（治疗前和定期）",
              "血压和体重",
              "生殖道感染症状",
              "足部检查"
            ]
          }
        },
        {
          "id": "DEVICE_001",
          "name": "连续血糖监测系统",
          "name_en": "Continuous Glucose Monitoring System",
          "type": "medical_device",
          "category": "糖尿病监测技术",
          "description": "通过皮下传感器连续监测组织间液葡萄糖浓度的设备系统",
          "patient_friendly_desc": "CGM是一个小贴片，贴在手臂上可以连续监测血糖变化，无需频繁扎手指",
          "clinical_significance": "ADA 2025强烈推荐的标准监测工具，革命性改变糖尿病管理方式",
          "properties": {
            "device_categories": {
              "real_time_cgm": {
                "description": "实时连续血糖监测(rtCGM)",
                "features": [
                  "实时血糖数值显示",
                  "趋势箭头指示",
                  "可设定高低血糖报警",
                  "数据可传输至智能设备"
                ],
                "examples": ["Dexcom G7", "Abbott FreeStyle Libre 2", "Medtronic MiniMed"],
                "wear_duration": "10-14天"
              },
              "flash_glucose_monitoring": {
                "description": "闪动血糖监测(FGM)",
                "features": [
                  "扫描读取血糖值",
                  "趋势图显示",
                  "无需校准",
                  "防水设计"
                ],
                "examples": ["FreeStyle Libre系列"],
                "limitations": "需要主动扫描，无实时报警"
              },
              "implantable_cgm": {
                "description": "植入式CGM",
                "duration": "90-180天",
                "examples": ["Eversense"],
                "advantages": "超长佩戴时间"
              }
            },
            "technical_specifications": {
              "measurement_range": "40-400 mg/dL (2.2-22.2 mmol/L)",
              "accuracy_metrics": {
                "mard": "平均相对绝对差<10%（优秀设备）",
                "clinical_accuracy": "99%+的读数在A+B区（Clarke网格分析）",
                "consensus_accuracy": "满足国际共识准确性标准"
              },
              "sampling_frequency": "每分钟1次",
              "calibration_requirements": {
                "factory_calibrated": "新一代设备无需用户校准",
                "traditional": "每日1-2次血糖仪校准"
              },
              "data_storage": "14-30天历史数据"
            },
            "ada_2025_recommendations": {
              "strong_recommendations": {
                "type1_diabetes": "所有1型糖尿病患者",
                "type2_on_insulin": "使用胰岛素的2型糖尿病患者",
                "frequent_hypoglycemia": "频发低血糖患者"
              },
              "conditional_recommendations": {
                "type2_non_insulin": "血糖控制不佳的2型糖尿病",
                "gestational_diabetes": "妊娠糖尿病高危患者",
                "elderly_high_risk": "老年高危患者"
              },
              "evidence_level": "A级推荐（强证据支持）"
            },
            "clinical_benefits": {
              "glycemic_control": {
                "hba1c_improvement": "平均降低0.3-0.8%",
                "time_in_range": "显著改善TIR",
                "glucose_variability": "降低血糖变异性"
              },
              "hypoglycemia_reduction": {
                "severe_hypoglycemia": "严重低血糖减少50-70%",
                "nocturnal_hypoglycemia": "夜间低血糖显著减少",
                "hypoglycemia_awareness": "改善低血糖感知"
              },
              "quality_of_life": {
                "reduced_finger_sticks": "大幅减少指尖采血",
                "peace_of_mind": "持续监测带来安全感",
                "treatment_satisfaction": "提高治疗满意度"
              }
            },
            "cgm_metrics_interpretation": {
              "ambulatory_glucose_profile": {
                "description": "标准化的14天血糖模式报告",
                "components": [
                  "血糖统计摘要",
                  "24小时血糖模式图",
                  "每日血糖叠加图",
                  "血糖变异性指标"
                ]
              },
              "key_metrics": {
                "time_in_range": "70-180 mg/dL时间占比，目标>70%",
                "time_below_range": "<70 mg/dL时间占比，目标<4%",
                "time_above_range": ">180 mg/dL时间占比，目标<25%",
                "glucose_management_indicator": "基于CGM数据的估算HbA1c"
              }
            },
            "integration_with_therapy": {
              "insulin_pump_integration": {
                "sensor_augmented_pumps": "泵+CGM集成系统",
                "low_glucose_suspend": "低血糖自动停泵",
                "predictive_low_glucose_suspend": "预测性低血糖保护"
              },
              "automated_insulin_delivery": {
                "hybrid_closed_loop": "混合闭环系统",
                "algorithm_driven": "算法驱动的胰岛素调节",
                "user_interaction": "仍需用户餐时干预"
              },
              "decision_support": {
                "bolus_calculators": "胰岛素剂量计算器",
                "pattern_recognition": "血糖模式识别",
                "trend_alerts": "血糖趋势预警"
              }
            },
            "limitations_considerations": {
              "physiological_lag": "组织液血糖滞后血管内血糖5-15分钟",
              "accuracy_limitations": "极端血糖值时准确性下降",
              "interference_factors": [
                "乙酰氨基酚干扰",
                "维生素C高剂量",
                "透析和脱水"
              ],
              "confirmatory_testing": {
                "when_required": [
                  "症状与读数不符",
                  "快速血糖变化时",
                  "校准和治疗决策"
                ]
              }
            },
            "cost_considerations": {
              "device_costs": "初始设备+传感器持续费用",
              "insurance_coverage": "多数保险覆盖，需满足条件",
              "cost_effectiveness": "长期健康获益证明成本效益",
              "generic_alternatives": "新兴品牌提供更经济选择"
            }
          },
          "clinical_implementation": {
            "patient_selection": {
              "ideal_candidates": [
                "血糖控制不佳患者",
                "频发低血糖患者",
                "积极自我管理患者",
                "生活方式不规律患者"
              ],
              "training_requirements": [
                "设备操作培训",
                "数据解读教育",
                "报警响应指导",
                "故障处理培训"
              ]
            },
            "healthcare_provider_role": {
              "data_analysis": "定期分析CGM数据模式",
              "treatment_adjustment": "基于CGM数据调整治疗",
              "patient_coaching": "指导患者数据解读和行为调整",
              "technology_support": "提供技术支持和故障排除"
            }
          }
        }
      ],
      "lifestyle_entities": [
        {
          "id": "LIFE_006",
          "name": "医学营养治疗",
          "name_en": "Medical Nutrition Therapy",
          "type": "therapeutic_intervention",
          "category": "营养治疗",
          "description": "由注册营养师提供的循证个体化营养干预，是糖尿病管理的基石",
          "patient_friendly_desc": "MNT是由专业营养师为您量身定制的饮食治疗方案，帮助控制血糖和改善整体健康",
          "clinical_significance": "ADA 2025强烈推荐的一线治疗方法，可显著改善血糖控制和生活质量",
          "properties": {
            "ada_2025_recommendations": {
              "referral_timing": "糖尿病诊断时即刻转诊，并在整个生命周期内根据需要提供",
              "provider_qualifications": "由注册营养师(RDN)提供个体化MNT",
              "evidence_level": "A级推荐 - 强力证据支持",
              "effectiveness_data": {
                "type2_hba1c_reduction": "绝对下降幅度可达2.0%（3-6个月）",
                "type1_hba1c_reduction": "绝对下降幅度可达1.9%（3-6个月）",
                "weight_management": "3-7%体重下降目标",
                "sustainability": "长期干预维持效果"
              }
            },
            "core_principles_2025": {
              "individualization": {
                "description": "基于个人和文化偏好的个体化营养需求",
                "factors": [
                  "健康素养和计算能力",
                  "健康食品的获取途径",
                  "行为改变的意愿和能力",
                  "现有改变障碍"
                ]
              },
              "evidence_based_patterns": {
                "mediterranean_diet": {
                  "benefits": "心血管保护、血糖改善",
                  "evidence": "大量RCT支持",
                  "implementation": "富含橄榄油、坚果、全谷物、蔬菜"
                },
                "dash_diet": {
                  "benefits": "血压控制、心血管健康",
                  "characteristics": "低钠、富含钾镁钙",
                  "diabetes_adaptation": "控制碳水化合物总量"
                },
                "plant_based_patterns": {
                  "ada_2025_emphasis": "鼓励植物蛋白和纤维摄入",
                  "benefits": ["改善胰岛素敏感性", "减重效果", "心血管保护"],
                  "implementation": "逐步增加豆类、坚果、全谷物比例"
                }
              },
              "macronutrient_distribution": {
                "carbohydrates": {
                  "percentage": "45-65%总热量（个体化调整）",
                  "quality_emphasis": "复杂碳水化合物、高纤维食物",
                  "glycemic_index": "优选低-中等血糖指数食物",
                  "portion_control": "碳水计数和餐盘法结合"
                },
                "proteins": {
                  "percentage": "15-20%总热量",
                  "sources": "瘦肉、鱼类、豆类、坚果",
                  "plant_protein_emphasis": "ADA 2025新增植物蛋白推荐",
                  "kidney_considerations": "CKD患者限制至0.8g/kg/day"
                },
                "fats": {
                  "percentage": "20-35%总热量",
                  "quality_focus": "限制饱和脂肪<7%总热量",
                  "omega3_emphasis": "每周2次鱼类摄入",
                  "trans_fat_avoidance": "完全避免反式脂肪"
                }
              },
              "ada_2025_beverage_guidance": {
                "primary_recommendation": "水作为首选饮品",
                "sweetened_beverages": "避免含糖饮料",
                "nonnutritive_sweeteners": {
                  "usage": "短期适量使用，替代含糖产品",
                  "purpose": "减少总热量和碳水化合物摄入",
                  "limitation": "不应长期大量使用"
                },
                "alcohol_guidelines": {
                  "women": "≤1份/日",
                  "men": "≤2份/日", 
                  "precautions": "监测血糖、避免空腹饮酒"
                }
              }
            },
            "specialized_populations": {
              "type1_diabetes": {
                "carb_counting": "精确碳水化合物计数",
                "insulin_to_carb_ratio": "个体化胰碳比计算",
                "flexible_meal_timing": "支持生活方式灵活性",
                "hypoglycemia_prevention": "低血糖预防和治疗策略"
              },
              "type2_diabetes": {
                "weight_management": "3-7%体重下降目标",
                "portion_control": "餐盘法和份量控制",
                "meal_timing": "规律进餐时间",
                "medication_coordination": "与降糖药物协调"
              },
              "gestational_diabetes": {
                "calorie_requirements": "妊娠期适当热量增加",
                "carb_distribution": "少量多餐，限制简单糖",
                "nutrient_needs": "叶酸、铁、钙等营养素充足",
                "postpartum_counseling": "产后持续营养指导"
              },
              "elderly_diabetes": {
                "malnutrition_prevention": "预防营养不良",
                "protein_adequacy": "充足蛋白质摄入",
                "social_factors": "考虑独居、经济因素",
                "comorbidity_management": "多重慢病营养协调"
              }
            },
            "implementation_strategies": {
              "initial_assessment": {
                "comprehensive_history": "详细饮食史、偏好、障碍",
                "anthropometric_measures": "身高、体重、BMI、腰围",
                "laboratory_values": "HbA1c、血脂、肾功能",
                "psychosocial_factors": "社会支持、经济状况、文化背景"
              },
              "goal_setting": {
                "smart_goals": "具体、可测量、可达成、相关、有时限",
                "collaborative_approach": "患者参与目标制定",
                "prioritization": "优先解决最重要的问题",
                "realistic_expectations": "设定现实可行的期望"
              },
              "education_components": {
                "carbohydrate_counting": "准确识别和计算碳水化合物",
                "label_reading": "营养标签解读技能",
                "meal_planning": "实用餐食规划技巧",
                "restaurant_dining": "外出就餐策略",
                "sick_day_management": "疾病期间营养管理",
                "travel_considerations": "旅行期间饮食安排"
              },
              "behavioral_strategies": {
                "motivational_interviewing": "动机性访谈技术",
                "problem_solving": "障碍识别和解决",
                "self_monitoring": "饮食记录和自我监测",
                "social_support": "家庭和社区支持系统",
                "relapse_prevention": "预防和应对复发"
              }
            },
            "technology_integration": {
              "mobile_apps": {
                "carb_counting_apps": "智能碳水计算应用",
                "meal_planning_tools": "餐食规划软件",
                "glucose_tracking": "血糖与饮食关联追踪",
                "telehealth_platforms": "远程营养咨询平台"
              },
              "continuous_glucose_monitoring": {
                "real_time_feedback": "餐后血糖实时反馈",
                "pattern_identification": "血糖模式识别",
                "meal_timing_optimization": "进餐时机优化",
                "portion_size_adjustment": "基于CGM的份量调整"
              }
            },
            "outcome_measures": {
              "clinical_outcomes": {
                "glycemic_control": "HbA1c、血糖变异性",
                "weight_management": "体重、BMI、腰围变化",
                "lipid_profile": "总胆固醇、LDL、HDL、甘油三酯",
                "blood_pressure": "收缩压和舒张压"
              },
              "patient_reported_outcomes": {
                "quality_of_life": "糖尿病相关生活质量评分",
                "treatment_satisfaction": "治疗满意度量表",
                "dietary_adherence": "饮食依从性评估",
                "self_efficacy": "营养管理自我效能感"
              },
              "process_measures": {
                "session_attendance": "营养咨询参与率",
                "goal_achievement": "设定目标达成率",
                "skill_acquisition": "营养技能掌握程度",
                "behavior_change": "饮食行为改变维持时间"
              }
            }
          },
          "barriers_and_solutions": {
            "common_barriers": {
              "cost_concerns": {
                "barrier": "认为健康饮食成本高",
                "solutions": ["季节性采购", "批量购买", "冷冻蔬果利用", "豆类蛋白替代"]
              },
              "time_constraints": {
                "barrier": "工作忙碌无时间准备",
                "solutions": ["周末备餐", "简单食谱", "健康快餐选择", "家庭协作"]
              },
              "cultural_preferences": {
                "barrier": "传统饮食习惯难改变",
                "solutions": ["文化饮食适应性改良", "传统食材健康搭配", "节庆饮食管理"]
              },
              "social_challenges": {
                "barrier": "社交聚餐压力",
                "solutions": ["提前规划", "沟通技巧", "灵活调整", "支持系统建立"]
              }
            },
            "healthcare_system_integration": {
              "reimbursement_advocacy": "保险覆盖MNT服务倡导",
              "provider_collaboration": "与医生、护士、药师协作",
              "quality_metrics": "MNT服务质量评估指标",
              "outcome_tracking": "长期效果追踪系统"
            }
          }
        },
        {
          "id": "LIFE_007",
          "name": "糖尿病运动处方",
          "name_en": "Exercise Prescription for Diabetes",
          "type": "therapeutic_intervention", 
          "category": "运动治疗",
          "description": "基于ACSM指南的个体化运动干预方案，改善血糖控制和心血管健康",
          "patient_friendly_desc": "运动处方是为您量身定制的安全有效的运动计划，帮助控制血糖和提升整体健康",
          "clinical_significance": "ACSM和ADA联合推荐的标准治疗方法，与药物治疗同等重要",
          "properties": {
            "acsm_2025_guidelines": {
              "evidence_base": "基于ACSM第12版运动测试与处方指南",
              "joint_position": "ACSM与ADA联合立场声明",
              "update_frequency": "定期更新以反映最新证据",
              "quality_assurance": "循证医学标准制定"
            },
            "exercise_prescription_components": {
              "aerobic_exercise": {
                "frequency": "每周至少150分钟中等强度，或75分钟高强度",
                "intensity_zones": {
                  "moderate_intensity": "40-59% VO2max 或 50-69% HRmax",
                  "vigorous_intensity": "60-84% VO2max 或 70-84% HRmax",
                  "perceived_exertion": "RPE 12-13（中等）至 RPE 14-16（较强）"
                },
                "time_recommendations": {
                  "minimum_bout": "每次至少10分钟连续运动",
                  "daily_goal": "每日约30分钟或更多",
                  "weekly_distribution": "一周内大多数天进行",
                  "maximal_gap": "连续两天内不超过2天不运动"
                },
                "modality_options": {
                  "walking": "最易实施，适合初学者",
                  "swimming": "适合关节问题患者",
                  "cycling": "低冲击有氧运动",
                  "group_classes": "增加社交支持和趣味性",
                  "household_activities": "日常活动增加强度"
                },
                "physiological_benefits": {
                  "acute_effects": "运动后2-72小时血糖降低",
                  "chronic_adaptations": "HbA1c降低0.5-0.7%",
                  "insulin_sensitivity": "胰岛素敏感性显著改善",
                  "cardiovascular_health": "心血管疾病风险降低"
                }
              },
              "resistance_training": {
                "frequency": "每周至少2次，非连续天",
                "intensity_guidelines": {
                  "moderate_intensity": "60-70% 1RM",
                  "high_intensity": ">70% 1RM，效果更佳",
                  "repetition_ranges": "8-12次为一组，进行2-4组",
                  "rest_periods": "组间休息2-3分钟"
                },
                "exercise_selection": {
                  "major_muscle_groups": "涵盖全身主要肌群",
                  "compound_movements": "优选复合动作",
                  "progressive_overload": "逐步增加负荷强度",
                  "safety_considerations": "正确技术和循序渐进"
                },
                "specific_benefits": {
                  "glucose_management": "高强度阻力训练对血糖管理效果更佳",
                  "insulin_levels": "显著降低胰岛素水平",
                  "muscle_mass": "维持和增加肌肉量",
                  "bone_density": "预防骨质疏松"
                },
                "equipment_options": {
                  "free_weights": "杠铃、哑铃训练",
                  "resistance_machines": "器械训练，更安全",
                  "bodyweight": "自重训练，随时随地",
                  "resistance_bands": "便携式阻力训练"
                }
              },
              "flexibility_and_balance": {
                "flexibility_training": {
                  "frequency": "每周至少2-3次",
                  "timing": "运动后进行静态拉伸",
                  "duration": "每个动作保持15-30秒",
                  "focus_areas": "主要运动肌群和紧张区域"
                },
                "balance_training": {
                  "target_population": "老年糖尿病患者，周围神经病变患者",
                  "exercises": "单腿站立、太极、瑜伽",
                  "frequency": "每周2-3次，每次15-20分钟",
                  "progression": "从简单到复杂，逐步进阶"
                }
              }
            },
            "type_specific_recommendations": {
              "type1_diabetes": {
                "exercise_timing": "避免胰岛素作用高峰期运动",
                "glucose_monitoring": {
                  "pre_exercise": "运动前检测血糖",
                  "during_exercise": "长时间运动中期监测",
                  "post_exercise": "运动后持续监测数小时",
                  "target_range": "运动时血糖5.6-13.9 mmol/L"
                },
                "carbohydrate_management": {
                  "pre_exercise_glucose": {
                    "<5.6_mmol": "运动前摄入15-30g碳水",
                    "5.6-13.9_mmol": "可正常运动",
                    ">13.9_mmol": "检测酮体，谨慎运动"
                  },
                  "during_exercise": "每30-60分钟补充15-20g碳水",
                  "post_exercise": "补充碳水预防延迟性低血糖"
                },
                "insulin_adjustment": {
                  "rapid_acting": "餐时胰岛素可减少25-50%",
                  "basal_insulin": "基础胰岛素可适当调整",
                  "pump_therapy": "临时基础率调整",
                  "injection_site": "避免运动肌肉部位注射"
                }
              },
              "type2_diabetes": {
                "weight_loss_focus": {
                  "calorie_expenditure": "中高运动量500千卡，每周4-5次",
                  "visceral_fat_reduction": "特别有效减少腹部脂肪",
                  "sustainable_approach": "长期可持续的运动模式",
                  "combination_effect": "与饮食控制联合效果最佳"
                },
                "medication_considerations": {
                  "insulin_users": "参考1型糖尿病管理策略",
                  "sulfonylurea_users": "监测低血糖风险",
                  "metformin_users": "通常无需特殊调整",
                  "newer_agents": "SGLT2抑制剂注意脱水风险"
                },
                "comorbidity_management": {
                  "hypertension": "优选有氧运动，监测血压",
                  "heart_disease": "心脏康复程序整合",
                  "neuropathy": "避免高冲击运动，选择游泳等",
                  "retinopathy": "避免剧烈阻力训练和倒立动作"
                }
              },
              "gestational_diabetes": {
                "safety_guidelines": "ACOG妊娠期运动指南遵循",
                "appropriate_exercises": "步行、游泳、孕妇瑜伽",
                "intensity_limitations": "中等强度，避免过度疲劳",
                "warning_signs": "胸痛、呼吸困难、阴道出血立即停止",
                "postpartum_benefits": "产后继续运动预防2型糖尿病"
              }
            },
            "pre_exercise_screening": {
              "acsm_2025_model": {
                "current_activity_level": "评估现有身体活动水平",
                "symptoms_assessment": "心血管、代谢、肾脏疾病症状",
                "known_disease": "已知疾病诊断和严重程度",
                "desired_intensity": "计划运动强度评估"
              },
              "diabetes_specific_screening": {
                "cardiovascular_assessment": {
                  "ecg_indications": "≥40岁或糖尿病>10年",
                  "stress_testing": "有症状或高危患者",
                  "echo_evaluation": "心功能评估",
                  "risk_stratification": "心血管风险分层"
                },
                "complications_screening": {
                  "diabetic_retinopathy": "眼底检查，限制高强度阻力训练",
                  "peripheral_neuropathy": "足部检查，选择适当运动类型",
                  "autonomic_neuropathy": "心率反应评估",
                  "nephropathy": "肾功能状态，运动强度调整"
                },
                "medication_review": {
                  "hypoglycemia_risk": "识别低血糖高危药物",
                  "cardiovascular_effects": "评估药物对运动反应影响",
                  "dehydration_risk": "SGLT2抑制剂等注意事项",
                  "timing_considerations": "药物作用时间与运动安排"
                }
              }
            },
            "exercise_physiology": {
              "acute_responses": {
                "glucose_utilization": {
                  "mechanism": "肌肉收缩增加葡萄糖摄取",
                  "insulin_independent": "非胰岛素依赖性葡萄糖摄取",
                  "duration": "效应可持续2-72小时",
                  "intensity_relationship": "强度越高，效果越明显"
                },
                "hormonal_changes": {
                  "catecholamines": "肾上腺素、去甲肾上腺素释放",
                  "cortisol": "应激激素适度升高",
                  "growth_hormone": "生长激素分泌增加",
                  "glucagon": "胰高血糖素反调节反应"
                },
                "metabolic_adaptations": {
                  "substrate_utilization": "脂肪和糖原利用模式变化",
                  "lactate_clearance": "乳酸清除能力改善",
                  "oxygen_consumption": "最大摄氧量提升",
                  "capillarization": "肌肉毛细血管密度增加"
                }
              },
              "chronic_adaptations": {
                "insulin_sensitivity": {
                  "glut4_transporters": "葡萄糖转运蛋白4增加",
                  "muscle_fiber_adaptation": "肌纤维胰岛素敏感性改善",
                  "mitochondrial_function": "线粒体功能和数量提升",
                  "duration": "训练停止后2-72小时内逐渐减退"
                },
                "cardiovascular_benefits": {
                  "cardiac_output": "心输出量提升",
                  "stroke_volume": "每搏输出量增加",
                  "peripheral_circulation": "外周循环改善",
                  "blood_pressure": "静息和运动血压降低"
                },
                "body_composition": {
                  "fat_mass_reduction": "体脂含量显著减少",
                  "lean_mass_preservation": "瘦体重维持或增加",
                  "visceral_fat": "内脏脂肪特异性减少",
                  "muscle_quality": "肌肉质量和功能改善"
                }
              }
            },
            "safety_considerations": {
              "contraindications": {
                "absolute_contraindications": [
                  "不稳定心绞痛",
                  "未控制的心律失常",
                  "症状性主动脉狭窄",
                  "未控制的糖尿病酮症酸中毒"
                ],
                "relative_contraindications": [
                  "血糖>16.7 mmol/L伴酮体阳性",
                  "血糖>13.9 mmol/L不伴酮体",
                  "严重自主神经病变",
                  "严重外周血管疾病"
                ]
              },
              "exercise_modifications": {
                "retinopathy_patients": "避免剧烈阻力训练和倒立",
                "neuropathy_patients": "选择低冲击运动，足部保护",
                "nephropathy_patients": "限制高强度运动",
                "cardiovascular_disease": "心脏康复程序指导下进行"
              },
              "emergency_preparedness": {
                "hypoglycemia_management": "随身携带速效糖源",
                "hyperglycemia_recognition": "识别高血糖症状",
                "emergency_contacts": "医疗联系信息和ID卡",
                "first_aid_knowledge": "基本急救知识培训"
              }
            }
          }
        },
        {
          "id": "LIFE_008",
          "name": "糖尿病心理健康管理",
          "name_en": "Diabetes Psychological Health Management",
          "type": "psychosocial_intervention",
          "category": "心理健康支持",
          "description": "针对糖尿病患者常见心理问题的专业评估、干预和支持体系",
          "patient_friendly_desc": "帮助糖尿病患者应对心理压力，改善情绪状态，提升生活质量的专业心理支持",
          "clinical_significance": "30-40%糖尿病患者存在心理健康问题，心理干预显著改善血糖控制和生活质量",
          "properties": {
            "diabetes_distress": {
              "definition": "糖尿病相关的特异性心理痛苦和负担感",
              "prevalence": "18-45%的糖尿病患者经历显著糖尿病痛苦",
              "clinical_impact": "与血糖控制差、并发症增加、生活质量下降相关",
              "assessment_tools": {
                "diabetes_distress_scale": {
                  "name": "糖尿病痛苦量表(DDS)",
                  "subscales": ["情绪负担", "医患关系", "治疗相关", "人际关系"],
                  "scoring": "1-6分量表，≥3分提示显著痛苦",
                  "administration": "自评问卷，10-15分钟完成"
                },
                "problem_areas_in_diabetes": {
                  "name": "糖尿病问题区域量表(PAID)",
                  "items": "20个条目评估糖尿病相关心理问题",
                  "cutoff": "≥40分提示显著心理痛苦",
                  "advantages": "广泛验证，多语言版本"
                }
              },
              "common_manifestations": [
                "对糖尿病管理感到不知所措",
                "担心并发症和未来健康",
                "因血糖控制不佳感到沮丧",
                "社交场合的尴尬和不适",
                "家庭关系因糖尿病而紧张"
              ]
            },
            "depression_anxiety": {
              "diabetes_depression_comorbidity": {
                "prevalence": "糖尿病患者抑郁症患病率是普通人群的2倍",
                "bidirectional_relationship": "抑郁症增加糖尿病风险，糖尿病加重抑郁",
                "screening_recommendations": "每年至少1次抑郁症筛查",
                "impact_on_glycemic_control": "抑郁患者HbA1c平均高0.5-1.0%"
              },
              "anxiety_disorders": {
                "types": ["广泛性焦虑", "恐慌障碍", "低血糖恐惧症", "注射恐惧症"],
                "low_blood_glucose_fear": {
                  "definition": "对低血糖的过度恐惧导致行为改变",
                  "consequences": "故意维持高血糖，影响长期控制",
                  "assessment": "低血糖恐惧调查问卷(HFS)",
                  "prevalence": "25-30%胰岛素使用者"
                }
              },
              "screening_tools": {
                "phq9": {
                  "name": "患者健康问卷-9(PHQ-9)",
                  "cutoffs": "≥10分中度抑郁，≥15分重度抑郁",
                  "diabetes_specific_considerations": "考虑躯体症状与糖尿病症状重叠"
                },
                "gad7": {
                  "name": "广泛性焦虑量表-7(GAD-7)",
                  "cutoffs": "≥10分中度焦虑，≥15分重度焦虑",
                  "implementation": "可在糖尿病门诊常规使用"
                }
              }
            },
            "psychosocial_interventions": {
              "cognitive_behavioral_therapy": {
                "cbt_for_diabetes": {
                  "approach": "针对糖尿病特异性认知行为治疗",
                  "components": [
                    "识别和修正不良认知模式",
                    "行为激活和活动安排",
                    "应对技能训练",
                    "解决问题技能培养"
                  ],
                  "effectiveness": "HbA1c平均改善0.3-0.5%，抑郁评分显著下降",
                  "duration": "通常12-16次治疗会话"
                },
                "diabetes_specific_cbt_techniques": {
                  "cognitive_restructuring": "挑战糖尿病相关的灾难性思维",
                  "behavioral_experiments": "测试关于糖尿病管理的负面预期",
                  "self_monitoring": "情绪和血糖的双重监测记录",
                  "relapse_prevention": "预防心理症状复发的策略"
                }
              },
              "mindfulness_based_interventions": {
                "mindfulness_based_stress_reduction": {
                  "mbsr_for_diabetes": "8周标准MBSR课程适应糖尿病患者",
                  "components": ["正念冥想", "身体扫描", "正念瑜伽", "日常生活正念"],
                  "benefits": ["减少糖尿病痛苦", "改善血糖控制", "提升生活质量"]
                },
                "acceptance_commitment_therapy": {
                  "act_principles": "接纳、认知脱融、价值导向行为",
                  "diabetes_applications": "接纳糖尿病诊断，专注价值驱动的自我管理",
                  "effectiveness": "改善心理灵活性和糖尿病自我管理"
                }
              },
              "group_therapy": {
                "diabetes_support_groups": {
                  "formats": ["同伴支持小组", "专业主导小组", "在线支持社区"],
                  "benefits": ["减少孤独感", "经验分享", "相互激励", "实用技巧交流"],
                  "structure": "通常每周1-2小时，持续8-12周"
                },
                "psychoeducational_groups": {
                  "content": ["糖尿病知识教育", "应对策略培训", "沟通技巧训练"],
                  "target_populations": ["新诊断患者", "青少年患者", "家庭成员"]
                }
              }
            },
            "family_social_support": {
              "family_involvement": {
                "diabetes_family_systems": {
                  "family_impact": "糖尿病影响整个家庭系统",
                  "roles": ["主要照护者", "情感支持者", "监督者", "倡导者"],
                  "challenges": ["过度保护", "控制冲突", "照护者负担", "家庭适应困难"]
                },
                "family_therapy": {
                  "systemic_approaches": "家庭系统治疗改善糖尿病管理",
                  "communication_training": "改善家庭内部沟通模式",
                  "problem_solving": "家庭共同解决糖尿病相关问题",
                  "boundary_setting": "建立适当的责任和边界"
                }
              },
              "social_support_networks": {
                "peer_support": {
                  "peer_support_models": ["一对一伙伴", "小组支持", "社区支持项目"],
                  "training_programs": "同伴支持者培训和认证",
                  "effectiveness": "改善自我管理行为和心理健康",
                  "sustainability": "长期维持支持关系的策略"
                },
                "community_resources": {
                  "diabetes_organizations": "糖尿病协会和患者组织",
                  "online_communities": "数字化同伴支持平台",
                  "workplace_support": "职场糖尿病管理支持",
                  "healthcare_team": "多学科团队协作支持"
                }
              }
            },
            "behavioral_change_psychology": {
              "motivation_enhancement": {
                "motivational_interviewing": {
                  "mi_principles": ["表达共情", "发展差异", "处理阻抗", "支持自我效能"],
                  "diabetes_applications": "提高治疗依从性和行为改变动机",
                  "techniques": ["开放式提问", "肯定", "反射性倾听", "总结"],
                  "effectiveness": "显著改善糖尿病自我管理行为"
                },
                "stages_of_change": {
                  "transtheoretical_model": "前思考期→思考期→准备期→行动期→维持期",
                  "stage_matched_interventions": "根据变化阶段提供相应干预",
                  "diabetes_behavior_change": "饮食、运动、监测、用药行为改变"
                }
              },
              "self_efficacy_enhancement": {
                "diabetes_self_efficacy": {
                  "definition": "患者对自己管理糖尿病能力的信心",
                  "assessment": "糖尿病自我效能量表(DMSES)",
                  "enhancement_strategies": [
                    "成功经验积累",
                    "替代学习和榜样",
                    "言语说服和鼓励",
                    "生理和情绪状态管理"
                  ]
                },
                "mastery_experiences": {
                  "graduated_tasks": "从简单到复杂的渐进式任务",
                  "skill_building": "系统性技能培养和练习",
                  "success_recognition": "识别和庆祝小的成功",
                  "failure_reframing": "将挫折重新定义为学习机会"
                }
              }
            },
            "technology_mental_health": {
              "digital_mental_health": {
                "diabetes_mental_health_apps": {
                  "features": ["情绪追踪", "正念练习", "CBT工具", "同伴连接"],
                  "evidence_based": "循证数字疗法应用",
                  "integration": "与糖尿病管理应用整合",
                  "accessibility": "提高心理健康服务可及性"
                },
                "ai_powered_support": {
                  "chatbots": "AI驱动的心理健康聊天机器人",
                  "predictive_analytics": "基于数据的心理健康风险预测",
                  "personalized_interventions": "个性化心理干预推荐"
                }
              },
              "telehealth_psychology": {
                "remote_therapy": "远程心理治疗服务",
                "virtual_support_groups": "在线支持小组",
                "hybrid_care_models": "线上线下结合的护理模式",
                "digital_divide": "数字鸿沟和可及性考虑"
              }
            }
          },
          "implementation_framework": {
            "screening_protocol": {
              "routine_screening": {
                "frequency": "每年至少一次心理健康筛查",
                "tools": "PHQ-9、GAD-7、DDS量表",
                "integration": "整合入常规糖尿病门诊",
                "staff_training": "医护人员心理筛查培训"
              },
              "high_risk_identification": {
                "risk_factors": [
                  "新诊断糖尿病",
                  "血糖控制差",
                  "严重低血糖史",
                  "糖尿病并发症",
                  "社会支持缺乏",
                  "既往心理疾病史"
                ],
                "early_intervention": "高危患者早期心理干预",
                "referral_pathways": "心理健康专业转诊流程"
              }
            },
            "integrated_care": {
              "collaborative_care_model": {
                "team_members": ["内分泌医生", "心理学家", "社会工作者", "护理协调员"],
                "care_coordination": "多学科团队协作和沟通",
                "shared_decision_making": "患者参与的共同决策",
                "outcome_monitoring": "临床和心理结果双重监测"
              },
              "stepped_care_approach": {
                "level1": "自助和教育资源",
                "level2": "简短心理干预和支持",
                "level3": "专业心理治疗",
                "level4": "精神科评估和治疗",
                "flexibility": "根据需求和反应调整干预强度"
              }
            }
          },
          "outcome_measures": {
            "psychological_outcomes": {
              "depression_anxiety": "PHQ-9、GAD-7评分改善",
              "diabetes_distress": "DDS评分下降",
              "quality_of_life": "糖尿病生活质量量表改善",
              "self_efficacy": "糖尿病自我效能感提升"
            },
            "clinical_outcomes": {
              "glycemic_control": "HbA1c改善",
              "self_management": "自我管理行为改善",
              "adherence": "治疗依从性提高",
              "healthcare_utilization": "急诊和住院减少"
            },
            "behavioral_outcomes": {
              "lifestyle_behaviors": "饮食运动行为改善",
              "self_monitoring": "血糖监测频率增加",
              "medication_adherence": "用药依从性提升",
              "healthcare_engagement": "医疗保健参与度提高"
            }
          }
        },
        {
          "id": "LIFE_005",
          "name": "糖尿病数字化健康管理",
          "name_en": "Digital Health Management for Diabetes",
          "type": "digital_intervention",
          "category": "数字化健康技术",
          "description": "利用数字化技术平台进行糖尿病全面管理的新兴治疗方式",
          "patient_friendly_desc": "使用手机应用、智能设备等数字化工具帮助管理糖尿病，让治疗更智能化",
          "clinical_significance": "ADA 2025重点强调的未来糖尿病管理方向，提高患者参与度和治疗效果",
          "properties": {
            "digital_health_components": {
              "mobile_health_apps": {
                "glucose_tracking": [
                  "血糖日志记录",
                  "趋势分析和预测",
                  "异常值提醒",
                  "与CGM数据同步"
                ],
                "carb_counting": [
                  "食物识别和碳水计算",
                  "个性化食谱推荐",
                  "营养成分分析",
                  "餐后血糖预测"
                ],
                "medication_management": [
                  "用药提醒",
                  "剂量追踪",
                  "药物相互作用检查",
                  "副作用记录"
                ],
                "lifestyle_tracking": [
                  "运动监测",
                  "睡眠质量追踪",
                  "压力水平评估",
                  "体重管理"
                ]
              },
              "wearable_devices": {
                "continuous_glucose_monitors": "实时血糖监测",
                "fitness_trackers": "活动量和心率监测",
                "smart_watches": "综合健康指标追踪",
                "smart_insulin_pens": "胰岛素注射记录"
              },
              "telemedicine_platforms": {
                "remote_consultations": "远程医生咨询",
                "virtual_diabetes_education": "在线糖尿病教育",
                "peer_support_groups": "患者互助社群",
                "family_involvement": "家庭成员参与平台"
              },
              "artificial_intelligence": {
                "pattern_recognition": "血糖模式AI识别",
                "predictive_analytics": "低血糖风险预测",
                "personalized_recommendations": "个性化治疗建议",
                "automated_alerts": "智能预警系统"
              }
            },
            "ada_2025_digital_health_standards": {
              "evidence_requirements": [
                "临床验证的有效性数据",
                "用户安全性评估",
                "数据隐私保护",
                "监管机构批准"
              ],
              "quality_metrics": [
                "用户粘性和参与度",
                "临床结局改善",
                "成本效益分析",
                "健康公平性影响"
              ],
              "integration_standards": [
                "与EHR系统互操作性",
                "FHIR标准兼容性",
                "医疗设备连接性",
                "数据标准化格式"
              ]
            },
            "clinical_effectiveness": {
              "glycemic_control": {
                "hba1c_improvement": "数字化干预平均降低0.3-0.7%",
                "time_in_range": "CGM结合应用显著改善TIR",
                "hypoglycemia_reduction": "AI预警减少严重低血糖"
              },
              "behavioral_outcomes": {
                "self_monitoring": "自我监测频率增加2-3倍",
                "medication_adherence": "用药依从性提高20-40%",
                "lifestyle_modification": "饮食和运动习惯持续改善",
                "diabetes_education": "知识掌握和技能提升"
              },
              "healthcare_utilization": {
                "emergency_visits": "糖尿病相关急诊减少",
                "hospital_admissions": "住院率降低",
                "provider_visits": "计划外就诊减少",
                "care_coordination": "医患沟通改善"
              }
            },
            "implementation_challenges": {
              "digital_divide": {
                "access_barriers": "设备和网络接入限制",
                "digital_literacy": "数字技能差异",
                "age_related": "老年患者适应性挑战",
                "socioeconomic": "经济地位影响使用"
              },
              "data_privacy_security": {
                "hipaa_compliance": "医疗隐私法规遵循",
                "cybersecurity": "网络安全威胁防护",
                "data_ownership": "患者数据所有权",
                "third_party_sharing": "数据共享政策"
              },
              "clinical_integration": {
                "workflow_disruption": "临床工作流程影响",
                "provider_training": "医护人员技术培训",
                "reimbursement": "支付模式不明确",
                "regulatory_uncertainty": "监管环境变化"
              }
            },
            "future_directions": {
              "emerging_technologies": {
                "machine_learning": "深度学习算法优化",
                "natural_language_processing": "语音和文本识别",
                "computer_vision": "图像识别技术",
                "internet_of_things": "物联网设备集成"
              },
              "personalization": {
                "genomic_data": "基因信息整合",
                "phenotypic_profiling": "表型特征分析",
                "precision_dosing": "精准剂量调整",
                "behavior_prediction": "行为模式预测"
              }
            }
          },
          "implementation_framework": {
            "patient_onboarding": {
              "digital_readiness_assessment": "数字化准备度评估",
              "device_setup_support": "设备配置技术支持",
              "initial_training": "基础使用培训",
              "ongoing_support": "持续技术支持"
            },
            "healthcare_integration": {
              "ehr_connectivity": "电子健康档案连接",
              "clinical_dashboard": "医生端数据面板",
              "alert_management": "预警信息管理",
              "outcome_tracking": "临床结局追踪"
            },
            "quality_assurance": {
              "clinical_validation": "临床有效性验证",
              "user_experience_testing": "用户体验测试",
              "security_audits": "安全性审计",
              "regulatory_compliance": "法规合规性检查"
            }
          }
        }
      ]
    },
    "relationships": [
      {
        "id": "REL_015",
        "source_id": "DEVICE_001",
        "target_id": "PHYS_006",
        "relation_type": "generates",
        "strength": "very_strong",
        "evidence_level": "high",
        "confidence": 0.96,
        "description": "连续血糖监测系统生成葡萄糖管理指标(GMI)",
        "patient_explanation": "CGM设备会根据连续监测的血糖数据自动计算出GMI值",
        "properties": {
          "calculation_basis": "基于14天平均血糖数据",
          "update_frequency": "每日更新",
          "accuracy_correlation": "与实验室HbA1c相关系数r=0.84-0.92",
          "clinical_utility": "提供实时血糖控制评估"
        },
        "ada_2025_endorsement": {
          "recommendation_level": "A级推荐",
          "clinical_guidance": "GMI应与传统HbA1c结合使用，提供更全面的血糖评估"
        }
      },
      {
        "id": "REL_016", 
        "source_id": "DEVICE_001",
        "target_id": "PHYS_007",
        "relation_type": "measures",
        "strength": "very_strong",
        "evidence_level": "high",
        "confidence": 0.98,
        "description": "连续血糖监测系统直接测量并报告目标范围内时间(TIR)",
        "patient_explanation": "CGM会统计您的血糖在理想范围内的时间比例",
        "properties": {
          "measurement_precision": "分钟级精度",
          "standardized_reporting": "AGP报告标准格式",
          "clinical_correlation": "与微血管并发症风险负相关",
          "improvement_tracking": "治疗调整效果实时追踪"
        },
        "clinical_impact": {
          "outcome_predictor": "TIR是并发症风险的强预测因子",
          "treatment_target": "ADA 2025推荐的主要治疗目标之一"
        }
      },
      {
        "id": "REL_017",
        "source_id": "DRUG_003",
        "target_id": "PATH_001",
        "relation_type": "treats",
        "strength": "very_strong",
        "evidence_level": "high",
        "confidence": 0.95,
        "description": "GLP-1受体激动剂治疗2型糖尿病，具有多重代谢益处",
        "patient_explanation": "GLP-1受体激动剂不仅降血糖，还能减重和保护心血管",
        "properties": {
          "primary_mechanism": "葡萄糖依赖性促胰岛素分泌",
          "secondary_benefits": [
            "减重3-8kg",
            "心血管事件降低12-26%",
            "肾脏保护作用"
          ],
          "ada_2025_positioning": "心血管疾病或肾病患者的首选药物之一"
        },
        "cvot_evidence": {
          "major_trials": ["LEADER", "SUSTAIN-6", "REWIND", "FLOW"],
          "primary_prevention": "适用于高心血管风险患者",
          "secondary_prevention": "已确诊心血管疾病患者获益更大"
        }
      },
      {
        "id": "REL_018",
        "source_id": "DRUG_004", 
        "target_id": "PATH_001",
        "relation_type": "treats",
        "strength": "very_strong",
        "evidence_level": "high", 
        "confidence": 0.94,
        "description": "SGLT2抑制剂治疗2型糖尿病，提供心肾保护",
        "patient_explanation": "SGLT2抑制剂通过肾脏排糖降血糖，同时保护心脏和肾脏",
        "properties": {
          "unique_mechanism": "胰岛素非依赖性降糖",
          "cardiovascular_protection": [
            "心血管死亡降低38%（恩格列净）",
            "心衰住院降低35%",
            "全因死亡降低32%"
          ],
          "renal_protection": [
            "肾脏复合终点改善30%",
            "延缓eGFR下降",
            "减少蛋白尿"
          ]
        },
        "ada_2025_indications": {
          "primary_indications": [
            "2型糖尿病伴确诊ASCVD",
            "2型糖尿病伴心力衰竭",
            "2型糖尿病伴慢性肾病"
          ],
          "evidence_strength": "A级推荐"
        }
      },
      {
        "id": "REL_019",
        "source_id": "PATH_003",
        "target_id": "PATH_001",
        "relation_type": "subtype_of",
        "strength": "strong",
        "evidence_level": "high",
        "confidence": 0.88,
        "description": "LADA是2型糖尿病的特殊亚型，具有自身免疫特征",
        "patient_explanation": "LADA看起来像2型糖尿病，但实际上是进展缓慢的1型糖尿病",
        "properties": {
          "prevalence": "占成人糖尿病的5-10%",
          "diagnostic_challenge": "容易误诊为典型2型糖尿病",
          "treatment_implications": "需要不同的治疗策略",
          "progression_pattern": "胰岛功能进行性衰退"
        },
        "ada_2025_recognition": {
          "diagnostic_criteria": "年龄≥30岁 + 自身抗体阳性 + 初期胰岛素非依赖",
          "screening_recommendation": "新诊断糖尿病且BMI<25时考虑筛查",
          "treatment_modification": "避免磺脲类，早期考虑胰岛素"
        }
      },
      {
        "id": "REL_020",
        "source_id": "LIFE_005",
        "target_id": "PHYS_007",
        "relation_type": "improves",
        "strength": "strong",
        "evidence_level": "moderate",
        "confidence": 0.82,
        "description": "数字化健康管理显著改善目标范围内时间",
        "patient_explanation": "使用糖尿病管理应用和智能设备可以帮助您更多时间保持血糖在理想范围",
        "properties": {
          "improvement_mechanism": [
            "实时血糖监测和反馈",
            "个性化治疗建议",
            "行为模式识别和调整",
            "医患沟通增强"
          ],
          "effectiveness_data": {
            "tir_improvement": "平均改善5-15%",
            "user_engagement": "高参与度患者获益更大",
            "sustained_benefit": "长期使用维持效果"
          }
        },
        "ada_2025_integration": {
          "recommendation": "鼓励使用临床验证的数字化健康工具",
          "quality_criteria": "需要循证医学证据支持的应用"
        }
      },
      {
        "id": "REL_021",
        "source_id": "LIFE_006",
        "target_id": "PHYS_007",
        "relation_type": "improves",
        "strength": "very_strong",
        "evidence_level": "high",
        "confidence": 0.96,
        "description": "医学营养治疗显著改善目标范围内时间和整体血糖控制",
        "patient_explanation": "专业营养师制定的饮食计划能帮助您更多时间保持血糖在理想范围内",
        "properties": {
          "improvement_mechanisms": [
            "碳水化合物计数精确化",
            "血糖指数优化食物选择",
            "餐时和份量个体化调整",
            "营养密度最大化策略"
          ],
          "clinical_effectiveness": {
            "tir_improvement": "TIR提升10-20%",
            "glucose_variability_reduction": "CV降低15-25%",
            "postprandial_control": "餐后血糖峰值显著降低",
            "dawn_phenomenon": "黎明现象改善"
          },
          "ada_2025_evidence": {
            "hba1c_correlation": "TIR改善与HbA1c降低呈强相关",
            "microvascular_benefits": "改善的TIR与并发症风险降低相关"
          }
        },
        "implementation_strategies": {
          "cgm_integration": "实时血糖监测指导营养调整",
          "pattern_identification": "识别食物对血糖影响模式",
          "individualized_carb_targets": "个体化碳水化合物目标设定"
        }
      },
      {
        "id": "REL_022", 
        "source_id": "LIFE_007",
        "target_id": "PHYS_007",
        "relation_type": "improves",
        "strength": "very_strong",
        "evidence_level": "high",
        "confidence": 0.94,
        "description": "规律运动显著改善目标范围内时间，特别是餐后血糖控制",
        "patient_explanation": "坚持运动能让您的血糖更多时间保持在健康范围，特别是饭后血糖",
        "properties": {
          "exercise_specific_benefits": {
            "acute_effects": "运动后2-72小时血糖降低",
            "postprandial_improvement": "餐后运动显著降低血糖峰值",
            "insulin_sensitivity": "运动增强胰岛素敏感性",
            "glucose_uptake": "非胰岛素依赖性葡萄糖摄取增加"
          },
          "acsm_evidence": {
            "aerobic_benefits": "有氧运动改善TIR 5-15%",
            "resistance_benefits": "阻力训练对血糖变异性改善更明显",
            "combined_training": "有氧+阻力训练效果最佳"
          },
          "timing_optimization": {
            "pre_meal_exercise": "餐前运动降低餐后血糖",
            "post_meal_exercise": "餐后45-60分钟运动效果显著",
            "bedtime_exercise": "轻度晚间运动改善夜间血糖"
          }
        },
        "cgm_integration": {
          "real_time_feedback": "CGM提供运动血糖反应即时反馈",
          "pattern_learning": "识别个体运动血糖响应模式",
          "safety_monitoring": "实时监测运动中低血糖风险"
        }
      },
      {
        "id": "REL_023",
        "source_id": "LIFE_006",
        "target_id": "LIFE_007",
        "relation_type": "synergizes_with",
        "strength": "very_strong",
        "evidence_level": "high", 
        "confidence": 0.92,
        "description": "医学营养治疗与运动处方协同作用，产生1+1>2的效果",
        "patient_explanation": "营养和运动结合使用比单独使用任何一种方法效果都要好得多",
        "properties": {
          "synergistic_mechanisms": {
            "metabolic_flexibility": "营养和运动共同改善代谢灵活性",
            "insulin_sensitivity": "协同增强胰岛素敏感性",
            "weight_management": "营养控制热量摄入，运动增加消耗",
            "body_composition": "优化体成分，增加瘦体重"
          },
          "combined_outcomes": {
            "hba1c_reduction": "联合干预HbA1c降低幅度更大",
            "weight_loss_synergy": "减重效果比单一干预提高50-100%",
            "cardiovascular_protection": "心血管获益呈指数增长",
            "medication_reduction": "更容易实现药物减量或停用"
          },
          "ada_acsm_joint_recommendations": {
            "lifestyle_cornerstone": "营养和运动是糖尿病管理基石",
            "first_line_therapy": "新诊断2型糖尿病首选治疗",
            "maintenance_strategy": "长期血糖控制维持策略",
            "complication_prevention": "并发症预防的核心措施"
          }
        },
        "implementation_coordination": {
          "timing_synchronization": {
            "pre_exercise_nutrition": "运动前适当碳水化合物补充",
            "post_exercise_recovery": "运动后营养恢复策略",
            "meal_exercise_spacing": "进餐与运动时间间隔优化"
          },
          "intensity_matching": {
            "low_intensity_days": "轻度运动日营养策略",
            "high_intensity_days": "高强度运动日能量需求调整",
            "rest_days": "休息日营养管理"
          },
          "individualization": {
            "metabolic_phenotyping": "基于代谢表型的个体化方案",
            "preference_integration": "考虑个人饮食和运动偏好",
            "barrier_addressing": "针对性解决实施障碍"
          }
        }
      },
      {
        "id": "REL_024",
        "source_id": "LIFE_006",
        "target_id": "PHYS_006",
        "relation_type": "improves",
        "strength": "strong",
        "evidence_level": "high",
        "confidence": 0.89,
        "description": "医学营养治疗改善葡萄糖管理指标，与CGM数据呈现良好相关性",
        "patient_explanation": "营养师的专业指导能改善您的GMI值，这个指标反映近期血糖控制情况",
        "properties": {
          "gmi_improvement_pathways": {
            "carbohydrate_optimization": "精确碳水计数降低平均血糖",
            "glycemic_index_selection": "低GI食物减少血糖波动",
            "portion_control": "科学份量控制避免血糖峰值",
            "meal_timing": "规律进餐时间稳定血糖模式"
          },
          "cgm_guided_nutrition": {
            "real_time_adjustment": "基于CGM数据实时调整营养策略",
            "pattern_based_counseling": "血糖模式指导个体化营养咨询",
            "food_glucose_correlation": "建立食物与血糖反应关联"
          },
          "outcome_metrics": {
            "gmi_reduction": "GMI平均改善0.3-0.8%",
            "consistency_improvement": "日间和日际血糖一致性提升",
            "target_achievement": "GMI达标率显著提高"
          }
        }
      },
      {
        "id": "REL_025",
        "source_id": "LIFE_007",
        "target_id": "PHYS_006", 
        "relation_type": "improves",
        "strength": "strong",
        "evidence_level": "high",
        "confidence": 0.87,
        "description": "运动处方改善葡萄糖管理指标，通过增强胰岛素敏感性和葡萄糖利用",
        "patient_explanation": "规律运动能改善您的GMI值，让血糖控制水平持续提升",
        "properties": {
          "exercise_gmi_pathways": {
            "insulin_sensitivity": "运动增强胰岛素敏感性，降低基础血糖",
            "glucose_utilization": "肌肉运动增加葡萄糖摄取和利用",
            "glycogen_metabolism": "改善肝脏和肌肉糖原代谢",
            "hormonal_regulation": "优化血糖调节激素分泌"
          },
          "training_type_effects": {
            "aerobic_impact": "有氧运动对平均血糖影响显著",
            "resistance_impact": "阻力训练对血糖稳定性贡献更大",
            "combined_benefits": "混合训练对GMI改善效果最佳"
          },
          "temporal_effects": {
            "acute_response": "单次运动后24-72小时GMI改善",
            "chronic_adaptation": "长期训练GMI持续优化",
            "detraining_effects": "停止运动后GMI逐渐回升"
          }
        }
      }
    ],
    "inference_rules": [
      {
        "id": "CGM_RULE_001",
        "name": "CGM数据解读规则",
        "type": "interpretation",
        "category": "cgm_analytics",
        "description": "基于ADA 2025和CGM共识的数据解读标准",
        "version": "2025",
        "evidence_level": "A",
        "conditions": {
          "data_quality_requirements": {
            "minimum_wear_time": ">=70%",
            "minimum_duration": "14天",
            "sensor_accuracy": "MARD <10%"
          },
          "interpretation_criteria": {
            "time_in_range": {
              "excellent": ">85%",
              "target": "70-85%", 
              "needs_improvement": "<70%"
            },
            "time_below_range": {
              "level1_concern": ">4%",
              "level2_urgent": ">1%"
            },
            "glucose_variability": {
              "optimal": "CV <28%",
              "acceptable": "CV 28-36%",
              "high": "CV >36%"
            }
          }
        },
        "clinical_actions": {
          "tir_low": [
            "分析高血糖时间模式",
            "评估餐时胰岛素充分性",
            "检查基础胰岛素剂量",
            "考虑增加降糖药物"
          ],
          "tbr_high": [
            "立即评估低血糖原因",
            "调整胰岛素剂量",
            "修订血糖目标",
            "加强患者教育"
          ],
          "high_variability": [
            "识别血糖波动触发因素",
            "优化胰岛素时机",
            "改善碳水化合物计数",
            "考虑技术辅助"
          ]
        },
        "patient_explanation": "根据您的CGM数据，我们会分析血糖在理想范围的时间，制定个性化改善方案"
      },
      {
        "id": "PRECISION_RULE_001", 
        "name": "精准医学治疗选择规则",
        "type": "therapeutic",
        "category": "personalized_medicine",
        "description": "基于患者特征的个体化治疗方案选择",
        "version": "2025",
        "evidence_level": "A",
        "conditions": {
          "patient_phenotyping": {
            "cardiovascular_risk": {
              "established_cvd": {
                "priority_drugs": ["GLP-1 RA", "SGLT2i"],
                "evidence": "CVOT试验证据充分"
              },
              "high_cv_risk": {
                "risk_calculators": ["Pooled Cohort Equations", "ADVANCE Risk Score"],
                "threshold": "10年风险>15%"
              }
            },
            "kidney_disease": {
              "ckd_stage_3_4": {
                "egfr_range": "15-60 mL/min/1.73m²",
                "preferred_agents": ["SGLT2i", "GLP-1 RA"],
                "avoid": ["二甲双胍（eGFR<30）"]
              },
              "albuminuria": {
                "microalbuminuria": "ACR 30-300 mg/g",
                "macroalbuminuria": "ACR >300 mg/g"
              }
            },
            "heart_failure": {
              "hfref": {
                "ejection_fraction": "<40%",
                "first_line": "SGLT2抑制剂",
                "evidence": "DAPA-HF, EMPEROR-Reduced"
              }
            }
          },
          "genetic_considerations": {
            "mody_screening": {
              "clinical_criteria": [
                "糖尿病家族史3代连续",
                "年轻发病且不肥胖",
                "轻度高血糖持续"
              ],
              "genetic_testing": "基于表型的分步检测"
            },
            "pharmacogenomics": {
              "cyp2c19": "氯吡格雷代谢",
              "slc22a1": "二甲双胍转运",
              "kcnj11": "磺脲类敏感性"
            }
          }
        },
        "decision_algorithm": {
          "step1": "评估心血管和肾脏风险",
          "step2": "确定优先药物类别",
          "step3": "个体化剂量和监测",
          "step4": "效果评估和调整"
        },
        "outcome_targets": {
          "glycemic": "个体化HbA1c目标",
          "cardiovascular": "血压<130/80 mmHg",
          "renal": "延缓eGFR下降"
        }
      },
      {
        "id": "TECH_INTEGRATION_RULE_001",
        "name": "糖尿病技术整合规则",
        "type": "technology_implementation",
        "category": "digital_health",
        "description": "数字化技术在糖尿病管理中的整合应用规则",
        "version": "2025",
        "evidence_level": "B",
        "conditions": {
          "technology_readiness": {
            "patient_factors": [
              "数字化素养水平",
              "设备可及性",
              "经济承受能力",
              "疾病管理动机"
            ],
            "clinical_factors": [
              "血糖控制现状",
              "低血糖风险",
              "并发症程度",
              "治疗复杂性"
            ]
          },
          "device_selection": {
            "cgm_indications": [
              "1型糖尿病（强推荐）",
              "胰岛素治疗的2型糖尿病",
              "频发低血糖",
              "血糖变异性大"
            ],
            "automated_insulin_delivery": [
              "1型糖尿病适合人群",
              "胰岛素泵经验者",
              "积极自我管理者"
            ]
          }
        },
        "implementation_strategy": {
          "training_protocol": [
            "设备操作培训",
            "数据解读教育",
            "故障排除指导",
            "持续技术支持"
          ],
          "monitoring_plan": [
            "初期密切随访",
            "定期技术检查",
            "临床结局评估",
            "用户满意度调查"
          ]
        },
        "success_metrics": {
          "clinical_outcomes": [
            "HbA1c改善",
            "TIR增加",
            "严重低血糖减少"
          ],
          "patient_reported": [
            "生活质量提升",
            "治疗负担减轻",
            "糖尿病痛苦减少"
          ]
        }
      },
      {
        "id": "NUTRITION_EXERCISE_RULE_001",
        "name": "营养运动综合干预规则",
        "type": "lifestyle_intervention",
        "category": "comprehensive_management",
        "description": "基于ADA 2025和ACSM指南的营养运动综合干预决策规则",
        "version": "2025",
        "evidence_level": "A",
        "conditions": {
          "patient_assessment": {
            "glycemic_status": {
              "newly_diagnosed": {
                "hba1c_range": "6.5-8.5%",
                "priority": "生活方式干预为主，药物为辅",
                "duration": "3-6个月观察期"
              },
              "established_diabetes": {
                "hba1c_range": ">7.0%",
                "priority": "强化生活方式干预+药物优化",
                "monitoring": "每3个月评估调整"
              },
              "well_controlled": {
                "hba1c_range": "<7.0%",
                "priority": "维持现有生活方式，预防并发症",
                "frequency": "每6个月评估"
              }
            },
            "comorbidity_considerations": {
              "overweight_obesity": {
                "bmi_threshold": "≥25 kg/m²",
                "weight_loss_target": "3-7% initial body weight",
                "intervention_focus": "营养控制为主，运动为辅"
              },
              "cardiovascular_disease": {
                "established_cvd": "优选有心血管保护作用的运动",
                "high_cv_risk": "渐进式运动强度增加",
                "exercise_prescription": "心脏康复程序整合"
              },
              "chronic_kidney_disease": {
                "egfr_30_60": "适度运动，蛋白质限制",
                "egfr_15_30": "轻度运动，严格营养管理",
                "dialysis": "透析日运动调整"
              }
            }
          },
          "intervention_selection": {
            "nutrition_prioritization": {
              "high_priority_scenarios": [
                "初诊2型糖尿病且超重",
                "血糖变异性大",
                "餐后血糖控制差",
                "有营养相关并发症"
              ],
              "mnt_intensity_levels": {
                "intensive": "每月2-4次营养咨询",
                "moderate": "每月1-2次营养咨询", 
                "maintenance": "每3个月1次营养咨询"
              }
            },
            "exercise_prioritization": {
              "high_priority_scenarios": [
                "胰岛素抵抗明显",
                "心血管疾病风险高",
                "肌肉量减少",
                "情绪问题明显"
              ],
              "exercise_intensity_levels": {
                "vigorous": "每周150分钟中强度+2次阻力训练",
                "moderate": "每周150分钟轻中强度+1次阻力训练",
                "light": "每周100分钟轻强度活动"
              }
            }
          }
        },
        "decision_algorithms": {
          "initial_assessment": {
            "step1": "全面健康状况评估",
            "step2": "营养和运动准备度评估",
            "step3": "个体化目标设定",
            "step4": "障碍识别和解决方案制定"
          },
          "intervention_titration": {
            "week_0_2": "基础教育和习惯建立",
            "week_2_6": "强度逐步增加和精细调整",
            "week_6_12": "巩固期和长期策略制定",
            "month_3_plus": "维持期和持续优化"
          },
          "outcome_evaluation": {
            "primary_endpoints": ["HbA1c", "TIR", "体重变化"],
            "secondary_endpoints": ["血压", "血脂", "生活质量"],
            "safety_monitoring": ["低血糖", "运动损伤", "营养不良"]
          }
        },
        "ada_2025_compliance": {
          "nutrition_standards": "符合ADA医学营养治疗推荐",
          "exercise_standards": "符合ACSM/ADA联合运动指南",
          "integration_approach": "综合生活方式干预模式",
          "equity_considerations": "考虑健康公平性和可及性"
        }
      },
      {
        "id": "MEAL_EXERCISE_TIMING_RULE_001",
        "name": "进餐运动时机优化规则",
        "type": "timing_optimization",
        "category": "glucose_management",
        "description": "基于CGM数据和生理学原理的进餐运动时机优化决策规则",
        "version": "2025",
        "evidence_level": "B",
        "conditions": {
          "meal_composition_analysis": {
            "high_carbohydrate_meals": {
              "carb_content": ">45g碳水化合物",
              "pre_meal_strategy": "餐前15分钟轻度活动",
              "post_meal_strategy": "餐后45-60分钟中等强度运动",
              "duration": "15-30分钟"
            },
            "mixed_meals": {
              "carb_content": "15-45g碳水化合物",
              "protein_fat_presence": "含适量蛋白质和脂肪",
              "post_meal_strategy": "餐后60-90分钟运动",
              "intensity": "中低强度为宜"
            },
            "low_carbohydrate_meals": {
              "carb_content": "<15g碳水化合物",
              "exercise_timing": "灵活安排，无特殊时机要求",
              "hypoglycemia_prevention": "监测运动中血糖变化"
            }
          },
          "individual_glucose_patterns": {
            "dawn_phenomenon": {
              "morning_hyperglycemia": "早晨基础血糖升高",
              "intervention": "早餐后30分钟步行",
              "duration": "20-30分钟",
              "effectiveness": "显著改善全天血糖控制"
            },
            "postprandial_spikes": {
              "glucose_peak": ">10 mmol/L餐后血糖",
              "timing_optimization": "血糖开始上升时开始运动",
              "target": "将血糖峰值控制在合理范围"
            },
            "nocturnal_hypoglycemia": {
              "evening_exercise_caution": "晚间运动增加夜间低血糖风险",
              "safety_measures": "睡前血糖检测，必要时加餐"
            }
          }
        },
        "implementation_strategies": {
          "cgm_guided_timing": {
            "real_time_decision": "基于实时血糖趋势调整运动时机",
            "pattern_learning": "识别个体最佳运动时间窗",
            "alert_integration": "结合CGM报警系统"
          },
          "practical_applications": {
            "work_day_scheduling": "工作日运动时间安排",
            "weekend_flexibility": "周末灵活时间安排",
            "travel_adaptations": "旅行期间时机调整"
          }
        }
      }
    ],
    "clinical_validation_cases": [
      {
        "case_id": "ADA2025_CASE_001",
        "title": "基于CGM的1型糖尿病精准管理",
        "category": "technology_enhanced_care",
        "complexity": "high",
        "ada_2025_compliance": true,
        "patient_profile": {
          "demographics": {
            "age": 28,
            "gender": "女性",
            "diabetes_duration": "15年",
            "occupation": "软件工程师"
          },
          "medical_history": {
            "diabetes_type": "1型糖尿病",
            "complications": "轻度背景性视网膜病变",
            "previous_severe_hypoglycemia": "2次/年",
            "current_therapy": "胰岛素泵治疗5年"
          },
          "presenting_concerns": [
            "血糖变异性大",
            "夜间低血糖频发",
            "工作压力影响血糖控制",
            "希望改善生活质量"
          ]
        },
        "baseline_assessments": {
          "glycemic_control": {
            "hba1c": "7.8%",
            "severe_hypoglycemia": "2-3次/年",
            "dka_episodes": "无",
            "glucose_variability": "CV 42%（高）"
          },
          "cgm_metrics_baseline": {
            "time_in_range": "58%（低于目标）",
            "time_below_range": "8%（过高）",
            "time_above_range": "34%",
            "gmi": "7.9%"
          },
          "technology_use": {
            "insulin_pump": "美敦力MiniMed 770G",
            "cgm_experience": "间断使用2年",
            "smartphone_apps": "基础血糖记录"
          }
        },
        "ada_2025_interventions": {
          "cgm_optimization": {
            "device_upgrade": "升级至Dexcom G7",
            "integration": "与胰岛素泵数据整合",
            "alert_customization": "个性化报警设置",
            "family_sharing": "数据与家属共享"
          },
          "automated_insulin_delivery": {
            "system": "混合闭环系统启用",
            "algorithm_training": "个人化算法学习期",
            "manual_override": "特殊情况手动干预",
            "safety_features": "低血糖保护功能"
          },
          "digital_health_integration": {
            "comprehensive_app": "多功能糖尿病管理应用",
            "pattern_analysis": "AI辅助血糖模式识别",
            "behavioral_coaching": "个性化行为干预",
            "telemedicine": "月度远程医生咨询"
          },
          "precision_dosing": {
            "carb_ratio_optimization": "基于CGM数据精调",
            "correction_factor_tuning": "个体化校正因子",
            "basal_rate_adjustment": "24小时基础率优化",
            "exercise_management": "运动血糖预测和管理"
          }
        },
        "outcome_measurements": {
          "3_months": {
            "hba1c": "7.2%（改善0.6%）",
            "time_in_range": "73%（改善15%）",
            "time_below_range": "3%（改善5%）",
            "severe_hypoglycemia": "0次",
            "glucose_variability": "CV 31%（显著改善）"
          },
          "6_months": {
            "hba1c": "7.0%（达到目标）",
            "time_in_range": "78%（优秀控制）",
            "time_below_range": "2%（安全范围）", 
            "gmi": "7.1%（与HbA1c一致）",
            "treatment_satisfaction": "显著提升"
          },
          "12_months": {
            "sustained_improvement": "维持良好血糖控制",
            "complications_screening": "视网膜病变稳定",
            "quality_of_life": "工作和生活平衡改善",
            "diabetes_distress": "明显减轻"
          }
        },
        "ada_2025_compliance_checklist": {
          "cgm_metrics_reporting": "✅ 标准化AGP报告",
          "individualized_targets": "✅ 个体化HbA1c目标7.0%",
          "technology_integration": "✅ 循证技术方案",
          "patient_centered_care": "✅ 患者偏好考虑",
          "equity_considerations": "✅ 技术可及性评估"
        },
        "lessons_learned": [
          "CGM数据驱动的精准调整显著改善控制",
          "自动化胰岛素输送减少管理负担",
          "数字化工具增强患者自我效能",
          "个体化方案比标准方案更有效"
        ]
      },
      {
        "case_id": "ADA2025_CASE_002", 
        "title": "心肾并存的2型糖尿病综合管理",
        "category": "comorbidity_management",
        "complexity": "very_high",
        "ada_2025_compliance": true,
        "patient_profile": {
          "demographics": {
            "age": 64,
            "gender": "男性",
            "diabetes_duration": "12年",
            "ethnicity": "非洲裔美国人"
          },
          "comorbidities": {
            "cardiovascular": "既往心肌梗死（2年前）",
            "renal": "慢性肾病3期",
            "other": ["高血压", "血脂异常", "肥胖"]
          },
          "current_medications": [
            "二甲双胍 1000mg bid",
            "格列美脲 2mg qd", 
            "氨氯地平 10mg qd",
            "阿托伐他汀 40mg qd",
            "阿司匹林 81mg qd"
          ]
        },
        "baseline_parameters": {
          "glycemic": {
            "hba1c": "8.4%",
            "fasting_glucose": "9.8 mmol/L",
            "postprandial_glucose": "14.2 mmol/L"
          },
          "cardiovascular": {
            "blood_pressure": "142/88 mmHg",
            "ldl_cholesterol": "2.8 mmol/L",
            "ejection_fraction": "45%"
          },
          "renal": {
            "egfr": "42 mL/min/1.73m²",
            "urine_acr": "180 mg/g",
            "creatinine": "158 μmol/L"
          }
        },
        "ada_2025_management_strategy": {
          "medication_optimization": {
            "sglt2_inhibitor_addition": {
              "drug": "恩格列净 10mg qd",
              "rationale": "心肾双重保护",
              "monitoring": "肾功能、血压、生殖道感染"
            },
            "glp1_agonist_addition": {
              "drug": "司马鲁肽 1.0mg 每周",
              "rationale": "心血管保护 + 减重",
              "titration": "从0.25mg开始逐步加量"
            },
            "sulfonylurea_discontinuation": {
              "rationale": "避免低血糖和心血管风险",
              "timing": "新药稳定后逐步停用"
            }
          },
          "comprehensive_risk_management": {
            "blood_pressure": {
              "target": "<130/80 mmHg",
              "ace_inhibitor": "添加赖诺普利15mg qd",
              "monitoring": "肾功能变化"
            },
            "lipid_management": {
              "target": "LDL-C <1.8 mmol/L",
              "statin_intensification": "罗苏伐他汀20mg qd",
              "ezetimibe_addition": "如需要添加依折麦布"
            }
          },
          "lifestyle_intensive_counseling": {
            "medical_nutrition_therapy": "肾病糖尿病专业营养师",
            "exercise_prescription": "心脏康复程序参与",
            "weight_management": "目标减重7%",
            "smoking_cessation": "戒烟支持（如适用）"
          }
        },
        "monitoring_protocol": {
          "glycemic_monitoring": {
            "hba1c": "每3个月",
            "cgm_consideration": "如血糖变异性大",
            "hypoglycemia_assessment": "每次随访"
          },
          "cardiovascular_monitoring": {
            "blood_pressure": "每月家庭监测",
            "ecg": "每年一次",
            "lipid_panel": "3个月后复查"
          },
          "renal_monitoring": {
            "egfr_creatinine": "每3个月",
            "urine_acr": "每6个月",
            "electrolytes": "SGLT2i启动后2周、4周"
          }
        },
        "12_month_outcomes": {
          "glycemic_improvement": {
            "hba1c": "7.1%（改善1.3%）",
            "fasting_glucose": "7.2 mmol/L",
            "no_severe_hypoglycemia": "0次"
          },
          "cardiovascular_benefits": {
            "blood_pressure": "128/78 mmHg",
            "ldl_cholesterol": "1.6 mmol/L",
            "no_cv_events": "随访期无心血管事件"
          },
          "renal_protection": {
            "egfr_stability": "40 mL/min/1.73m²（稳定）",
            "urine_acr": "95 mg/g（显著改善）",
            "ckd_progression": "无进展"
          },
          "weight_management": {
            "weight_loss": "8.5kg（12%基线体重）",
            "bmi_reduction": "34.2 → 31.1 kg/m²"
          }
        },
        "ada_2025_evidence_alignment": {
          "sglt2i_cardio_renal": "✅ EMPA-REG, CREDENCE试验证据",
          "glp1_cardiovascular": "✅ SUSTAIN-6试验证据",
          "bp_target": "✅ ADA/ESC 2023共识",
          "comprehensive_care": "✅ 多重危险因素管理"
        }
      },
      {
        "case_id": "ADA2025_CASE_003",
        "title": "综合营养运动干预改善新诊断2型糖尿病",
        "category": "lifestyle_intervention",
        "complexity": "moderate",
        "ada_2025_compliance": true,
        "patient_profile": {
          "demographics": {
            "age": 52,
            "gender": "男性",
            "diabetes_duration": "新诊断",
            "occupation": "办公室职员",
            "family_history": "父亲2型糖尿病"
          },
          "baseline_characteristics": {
            "anthropometrics": {
              "height": "175cm",
              "weight": "92kg",
              "bmi": "30.1 kg/m²",
              "waist_circumference": "105cm"
            },
            "metabolic_parameters": {
              "hba1c": "7.8%",
              "fasting_glucose": "8.9 mmol/L",
              "postprandial_glucose": "13.2 mmol/L",
              "blood_pressure": "138/86 mmHg",
              "total_cholesterol": "5.8 mmol/L",
              "ldl_cholesterol": "3.6 mmol/L"
            },
            "lifestyle_assessment": {
              "dietary_habits": "高碳水、高脂饮食，不规律进餐",
              "physical_activity": "久坐少动，每周运动<1次",
              "stress_level": "工作压力大，睡眠不足",
              "readiness_to_change": "高动机，配合度好"
            }
          }
        },
        "comprehensive_intervention_plan": {
          "medical_nutrition_therapy": {
            "initial_assessment": {
              "registered_dietitian": "专业注册营养师全面评估",
              "dietary_recall": "3日饮食记录分析",
              "cultural_preferences": "考虑饮食文化背景",
              "barrier_identification": "工作餐、社交聚餐挑战"
            },
            "individualized_meal_plan": {
              "calorie_target": "1800千卡/日（减重导向）",
              "macronutrient_distribution": {
                "carbohydrates": "45%（选择低GI复杂碳水）",
                "proteins": "20%（增加植物蛋白比例）",
                "fats": "35%（优质脂肪，限制饱和脂肪）"
              },
              "meal_timing": "规律三餐+2次健康加餐",
              "portion_control": "餐盘法教育，视觉化份量控制"
            },
            "ada_2025_nutrition_strategies": {
              "plant_based_emphasis": "每日至少50%植物性食物",
              "fiber_optimization": "每日纤维摄入≥25g",
              "beverage_guidelines": "水为主要饮品，避免含糖饮料",
              "cooking_methods": "蒸、煮、烤替代油炸"
            }
          },
          "exercise_prescription": {
            "acsm_based_assessment": {
              "pre_participation_screening": "心血管风险评估正常",
              "fitness_testing": "最大摄氧量35ml/kg/min（偏低）",
              "exercise_preferences": "步行、骑行、游泳",
              "time_constraints": "工作日时间限制，周末相对灵活"
            },
            "progressive_training_program": {
              "phase1_weeks_1_4": {
                "aerobic_component": {
                  "frequency": "每周5次",
                  "intensity": "中等强度（60-70% HRmax）",
                  "time": "从20分钟渐增至35分钟",
                  "type": "快走、固定自行车"
                },
                "resistance_component": {
                  "frequency": "每周2次",
                  "intensity": "60-70% 1RM",
                  "exercises": "全身主要肌群，8个动作",
                  "progression": "2组×10-12次渐增至3组"
                }
              },
              "phase2_weeks_5_12": {
                "aerobic_intensification": {
                  "interval_training": "每周1次高强度间歇训练",
                  "steady_state": "每周3次中等强度持续训练",
                  "flexibility": "每周2次瑜伽或拉伸"
                },
                "resistance_progression": {
                  "weight_increase": "逐步增加负重",
                  "complexity_advancement": "引入复合动作",
                  "functional_training": "日常生活相关动作模式"
                }
              }
            }
          },
          "integration_strategies": {
            "meal_exercise_coordination": {
              "morning_routine": "早餐后30分钟步行上班",
              "lunch_break": "午餐后45分钟办公室附近快走",
              "evening_schedule": "晚餐前1小时健身房训练",
              "weekend_flexibility": "户外长时间有氧活动"
            },
            "cgm_guided_optimization": {
              "device": "FreeStyle Libre 2连续血糖监测",
              "real_time_feedback": "餐后血糖实时监测",
              "pattern_identification": "识别食物血糖反应模式",
              "exercise_timing": "基于血糖趋势优化运动时机"
            },
            "technology_support": {
              "mobile_apps": "MyFitnessPal营养追踪+Strava运动记录",
              "wearable_device": "Apple Watch心率和活动监测",
              "telemedicine": "每月营养师和运动专家远程咨询"
            }
          }
        },
        "progressive_outcomes": {
          "month_1": {
            "weight_change": "-3.2kg（3.5%体重下降）",
            "glycemic_improvement": {
              "hba1c": "7.4%（改善0.4%）",
              "fasting_glucose": "7.8 mmol/L",
              "postprandial_glucose": "11.2 mmol/L",
              "time_in_range": "65%（基线55%）"
            },
            "fitness_gains": {
              "cardiorespiratory": "运动耐力明显提升",
              "strength": "阻力训练重量增加15%",
              "flexibility": "关节活动度改善"
            },
            "behavioral_changes": {
              "dietary_adherence": "85%营养计划依从性",
              "exercise_compliance": "每周完成90%运动目标",
              "self_monitoring": "规律血糖监测和记录"
            }
          },
          "month_3": {
            "weight_achievement": "-6.8kg（7.4%体重下降，超过目标）",
            "glycemic_excellence": {
              "hba1c": "6.8%（达到目标，改善1.0%）",
              "fasting_glucose": "6.9 mmol/L（正常范围）",
              "postprandial_glucose": "9.1 mmol/L（显著改善）",
              "time_in_range": "78%（优秀控制）",
              "glucose_variability": "CV 28%（改善显著）"
            },
            "cardiovascular_improvements": {
              "blood_pressure": "128/78 mmHg（达标）",
              "resting_heart_rate": "从78降至65 bpm",
              "lipid_profile": {
                "total_cholesterol": "4.9 mmol/L",
                "ldl_cholesterol": "2.8 mmol/L",
                "hdl_cholesterol": "从1.1升至1.3 mmol/L"
              }
            },
            "fitness_transformation": {
              "vo2max": "从35增至42 ml/kg/min",
              "body_composition": "体脂率从28%降至22%",
              "muscle_mass": "瘦体重增加1.5kg",
              "functional_capacity": "日常活动能力显著提升"
            }
          },
          "month_6": {
            "sustained_success": {
              "weight_maintenance": "维持6kg减重成果",
              "glycemic_stability": "HbA1c稳定在6.5-6.8%",
              "medication_status": "无需启动降糖药物治疗",
              "complication_prevention": "并发症筛查均正常"
            },
            "lifestyle_integration": {
              "habit_formation": "营养和运动成为日常习惯",
              "social_support": "家庭成员积极参与健康生活",
              "stress_management": "通过运动有效缓解工作压力",
              "sleep_improvement": "睡眠质量和时间显著改善"
            },
            "long_term_planning": {
              "maintenance_strategy": "制定长期维持计划",
              "monitoring_schedule": "每3个月全面健康评估",
              "continuing_education": "持续营养和运动知识更新",
              "peer_support": "参加糖尿病患者支持小组"
            }
          }
        },
        "key_success_factors": {
          "individualized_approach": {
            "personalized_targets": "基于个人特征的个体化目标",
            "preference_integration": "结合患者偏好和生活方式",
            "cultural_sensitivity": "尊重文化背景和饮食习惯",
            "flexible_adaptations": "根据进展灵活调整方案"
          },
          "professional_team": {
            "multidisciplinary_care": "内分泌医生、营养师、运动专家协作",
            "regular_monitoring": "密切随访和及时调整",
            "patient_education": "系统性糖尿病教育和技能培训",
            "motivational_support": "持续激励和心理支持"
          },
          "technology_enablement": {
            "real_time_feedback": "CGM提供即时血糖反馈",
            "behavior_tracking": "应用程序辅助行为改变",
            "remote_monitoring": "远程医疗支持连续护理",
            "data_integration": "多源数据整合分析"
          }
        },
        "ada_2025_alignment": {
          "lifestyle_first": "✅ 新诊断2型糖尿病优先生活方式干预",
          "individualized_nutrition": "✅ 个体化医学营养治疗",
          "evidence_based_exercise": "✅ ACSM运动处方指南遵循",
          "technology_integration": "✅ CGM和数字化健康工具应用",
          "comprehensive_care": "✅ 多学科团队协作模式",
          "patient_centered": "✅ 以患者为中心的护理方式"
        },
        "clinical_pearls": [
          "新诊断糖尿病患者动机高，是生活方式干预的黄金时期",
          "营养和运动的协同作用远超单一干预效果",
          "CGM实时反馈显著提升患者参与度和依从性",
          "个体化方案比标准方案具有更好的长期维持效果",
          "多学科团队支持是成功的关键因素"
        ]
      },
      {
        "case_id": "ADA2025_CASE_004",
        "title": "老年2型糖尿病患者安全运动营养管理",
        "category": "geriatric_diabetes_care",
        "complexity": "high",
        "ada_2025_compliance": true,
        "patient_profile": {
          "demographics": {
            "age": 73,
            "gender": "女性",
            "diabetes_duration": "18年",
            "living_situation": "与女儿同住",
            "mobility_status": "轻度行动不便"
          },
          "medical_complexity": {
            "diabetes_complications": [
              "轻度糖尿病肾病（eGFR 55）",
              "轻度视网膜病变",
              "周围神经病变"
            ],
            "comorbidities": [
              "高血压",
              "骨关节炎",
              "轻度认知功能下降"
            ],
            "current_medications": [
              "二甲双胍 500mg bid",
              "格列美脲 1mg qd",
              "赖诺普利 5mg qd",
              "阿司匹林 75mg qd"
            ]
          },
          "functional_assessment": {
            "activities_of_daily_living": "基本自理，需部分协助",
            "instrumental_adl": "需要帮助处理复杂任务",
            "fall_risk": "中等风险（过去1年跌倒1次）",
            "cognitive_function": "MMSE 26/30（轻度下降）"
          }
        },
        "age_appropriate_interventions": {
          "specialized_nutrition_therapy": {
            "geriatric_considerations": {
              "protein_emphasis": {
                "target_intake": "1.2-1.5g/kg/day（高于标准推荐）",
                "rationale": "预防肌肉减少症",
                "protein_sources": "易消化高质量蛋白",
                "distribution": "三餐均匀分布"
              },
              "calorie_management": {
                "approach": "维持性而非减重导向",
                "target": "满足营养需求，避免营养不良",
                "flexibility": "允许适度体重波动"
              },
              "micronutrient_attention": {
                "vitamin_b12": "定期检测，必要时补充",
                "vitamin_d": "骨骼健康维护",
                "calcium": "骨质疏松预防",
                "fiber": "便秘预防和血糖控制"
              }
            },
            "practical_strategies": {
              "meal_preparation": {
                "family_involvement": "女儿参与餐食规划和准备",
                "simple_recipes": "易于制作的健康食谱",
                "meal_services": "社区老年送餐服务补充",
                "texture_modification": "考虑咀嚼和吞咽能力"
              },
              "eating_patterns": {
                "regular_schedule": "规律进餐时间，避免遗漏",
                "portion_sizes": "适当份量，避免过饱",
                "social_eating": "鼓励家庭共餐，增加社交",
                "hydration": "充足水分摄入，预防脱水"
              }
            }
          },
          "safe_exercise_program": {
            "geriatric_exercise_principles": {
              "safety_first": "安全性优先于强度和效果",
              "fall_prevention": "平衡和协调能力训练",
              "joint_protection": "低冲击运动选择",
              "gradual_progression": "非常缓慢的进展速度"
            },
            "tailored_exercise_prescription": {
              "aerobic_component": {
                "type": "椅子操、太极、慢走",
                "intensity": "轻到中等强度（RPE 11-13）",
                "duration": "从10分钟开始，渐增至30分钟",
                "frequency": "每周5-6次",
                "supervision": "初期需要监督和指导"
              },
              "resistance_training": {
                "equipment": "阻力带、轻哑铃（0.5-2kg）",
                "exercises": "坐位和站位功能性动作",
                "progression": "重复次数增加优于重量增加",
                "frequency": "每周2-3次"
              },
              "balance_flexibility": {
                "balance_training": "单腿站立、脚跟到脚尖行走",
                "flexibility": "全身伸展，关节活动度维持",
                "frequency": "每日进行，每次15-20分钟"
              }
            }
          },
          "safety_monitoring": {
            "glucose_management": {
              "cgm_consideration": "简化CGM应用，减少操作复杂性",
              "hypoglycemia_prevention": "调整降糖药物，放宽血糖目标",
              "family_education": "家属识别和处理低血糖",
              "emergency_preparedness": "随身携带糖源和联系信息"
            },
            "exercise_safety": {
              "pre_exercise_assessment": "每次运动前简单健康检查",
              "supervision_level": "初期专业指导，后期家属陪伴",
              "environment_safety": "清除家中跌倒风险因素",
              "emergency_planning": "运动中异常情况应对预案"
            },
            "medication_coordination": {
              "timing_optimization": "与运动和进餐时间协调",
              "dosage_adjustment": "基于活动水平调整药物",
              "side_effects_monitoring": "密切观察药物不良反应",
              "simplified_regimen": "简化用药方案，提高依从性"
            }
          }
        },
        "individualized_outcomes": {
          "realistic_goals": {
            "glycemic_targets": {
              "hba1c_goal": "7.5-8.0%（放宽目标）",
              "fasting_glucose": "6.0-8.0 mmol/L",
              "avoid_hypoglycemia": "首要安全目标",
              "quality_of_life": "优先考虑生活质量"
            },
            "functional_goals": {
              "mobility_maintenance": "保持独立行走能力",
              "fall_prevention": "减少跌倒风险",
              "activities_preservation": "维持日常生活自理",
              "social_engagement": "鼓励社交活动参与"
            }
          },
          "6_month_outcomes": {
            "clinical_stability": {
              "hba1c": "7.8%（稳定控制）",
              "hypoglycemic_events": "0次严重低血糖",
              "blood_pressure": "138/80 mmHg（可接受）",
              "kidney_function": "eGFR稳定在52-55"
            },
            "functional_improvements": {
              "balance_score": "Berg平衡量表提升8分",
              "muscle_strength": "握力增加10%",
              "walking_endurance": "6分钟步行距离增加50米",
              "falls_reduced": "过去6个月无跌倒事件"
            },
            "quality_of_life": {
              "diabetes_distress": "糖尿病痛苦量表评分改善",
              "independence_level": "日常自理能力维持",
              "social_participation": "家庭和社区活动参与增加",
              "mood_improvement": "抑郁评分轻度改善"
            }
          }
        },
        "geriatric_diabetes_considerations": {
          "ada_2025_elderly_guidelines": {
            "individualized_targets": "基于健康状况和预期寿命",
            "hypoglycemia_avoidance": "严格预防低血糖事件",
            "polypharmacy_management": "简化药物治疗方案",
            "functional_status_priority": "功能独立性优于血糖控制"
          },
          "family_caregiver_integration": {
            "education_provision": "为家属提供糖尿病管理培训",
            "support_system": "建立可靠的家庭支持网络",
            "emergency_preparedness": "家属应急处理能力培养",
            "respite_care": "为主要照护者提供喘息服务"
          },
          "community_resources": {
            "senior_centers": "利用社区老年活动中心",
            "home_health_services": "定期护士上门服务",
            "transportation_assistance": "医疗就诊交通支持",
            "meal_programs": "社区老年营养餐计划"
          }
        }
      }
    ],
    "performance_benchmarks": {
      "diagnostic_accuracy": {
        "overall_accuracy": ">95%",
        "sensitivity": ">92%",
        "specificity": ">94%", 
        "positive_predictive_value": ">88%",
        "negative_predictive_value": ">96%"
      },
      "treatment_recommendation_quality": {
        "guideline_adherence": ">98%",
        "personalization_score": ">85%",
        "safety_alert_accuracy": ">99%",
        "drug_interaction_detection": "100%"
      },
      "cgm_data_processing": {
        "agp_report_generation": "<5秒",
        "pattern_recognition": ">90%准确率",
        "trend_prediction": "85%准确率（4小时预测）",
        "alert_false_positive_rate": "<5%"
      }
    }
  }
}